


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update May 25 - May 31, 2020,
PhD

Dr. Peter J. Lansberg MD,
PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 22 2020

709 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashbord](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford Universtiy Press](#)

[Cambridge Univeristy Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

Mainstream Media

[U.S. plans massive coronavirus vaccine testing to meet year-end deadline \(Reuters\)](#)

[Japan's 3 Cs—closed spaces, crowds, and close-contact settings \(Science\)](#)

[Alzheimer's Gene \(E2/E2\) Linked to Higher Risk of Severe COVID-19 \(Scientist\)](#)

[COVID-19 Vaccine Researchers Mindful of Immune Enhancement \(Scientist\)](#)
[Hydroxychloroquine study questioned by 120 researchers \(Guardian\)](#)
[The World Is Still Far From Herd Immunity for Coronavirus \(NYT\)](#)
[What's the Risk of Catching Coronavirus From a Surface? \(NYT\)](#)
[Masks helped keep Japan's COVID-19 death toll low, says expert panel](#)
[There will probably be a second wave \(Guardian\)](#)
[Death threats after a trial on chloroquine for COVID-19 \(Lancet\)](#)
[genomics to help avoid a second coronavirus wave \(Nature\)](#)
[Ethical guidelines for COVID-19 tracing apps \(Nature\)](#)
[It's Not Whether You Were Exposed to the Virus. It's How Much \(NYT\)](#)
[Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere \(Scientist\)](#)
[Researchers Applaud Spanish COVID-19 Serological Survey \(Scientist\)](#)
[Genetic risk factors for Alzheimer's also raise the risk of getting COVID-19 \(Science\)](#)
[How to Improve and Protect Nursing Homes From Outbreaks \(NYT\)](#)
[Karl Friston: 'Germany may have more immunological "dark matter" \(Guardian\)](#)

KeyArticles

- 1. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.** *Viruses* 2020; 12Younes N, Al-Sadeq DW, Al-Jighefee H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32466458>
- 2. Early risk factors of the exacerbation of Coronavirus disease 2019 pneumonia.** *J Med Virol* 2020; Wang CZ, Hu SL, Wang L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32470167>
- 3. The Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19) - a Systematic Echocardiographic Study.** *Circulation* 2020; Szekely Y, Lichter Y, Taieb P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469253>
- 4. Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis.** *Am. J. Epidemiol.* 2020; Risch HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458969>
- 5. Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring.** *J Am Heart Assoc* 2020:e017144Ramireddy A, Chugh H, Reinier K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32463348>
- 6. COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns.** *Pain Ther* 2020; Pergolizzi JV, Jr., Varrassi G, Magnusson P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32447629>
- 7. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options**

related to the renin-angiotensin system. Eur Heart J Cardiovasc Pharmacother 2020; Offringa A, Montijn R, Singh S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32464637>

8. **Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.** Int J Environ Res Public Health 2020; 17Mirabelli M, Chiefari E, Puccio L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456064>
9. **Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.** Nutr. Metab. Cardiovasc. Dis. 2020; Li M, Dong Y, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456948>
10. **Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes.** Am J Physiol Endocrinol Metab 2020; Korakas E, Ikonomidis I, Kousathana F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32459524>
11. **Predictors for Severe COVID-19 Infection.** Clin Infect Dis 2020; Bhargava A, Fukushima EA, Levine M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472676>
12. **Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.** J. Thromb. Thrombolysis 2020; Artifoni M, Danic G, Gautier G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451823>

Basic Science (23 articles)

1. **Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.** Aging (Albany NY) 2020; 12Menendez JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463794>
2. **A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization.** Biochem. Biophys. Res. Commun. 2020; Bongini P, Trezza A, Bianchini M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32451080>
3. **Stability of RNA sequences derived from the coronavirus genome in human cells.** Biochem. Biophys. Res. Commun. 2020; Wakida H, Kawata K, Yamaji Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446559>
4. **Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.** Biomedicines 2020; 8Glinsky GV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455629>
5. **Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology.** Br. J. Pharmacol. 2020; Cleary SJ, Pitchford SC, Amison RT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462701>
6. **Metatranscriptomic Characterization of COVID-19 Identified A Host Transcriptional Classifier Associated With Immune Signaling.** Clin Infect Dis 2020; Zhang H, Ai JW, Yang W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32463434>
7. **Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.** Electrophoresis 2020; Scheller C, Krebs F, Minkner R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32469436>
8. **SARS-CoV-2 Phylogenetic Analysis, Lazio Region, Italy, February-March 2020.** Emerg Infect Dis 2020; 26Bartolini B, Rueca M, Gruber CEM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459984>
9. **Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection.** Exp. Mol. Pathol. 2020:104474Lavi E, Cong L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454103>
10. **High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.** Int. J. Biol. Macromol. 2020; Naik B, Gupta N, Ojha R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32470577>
11. **ACE2, TMPRSS2 AND FURIN GENE EXPRESSION IN THE AIRWAYS OF PEOPLE WITH ASTHMA - IMPLICATIONS FOR COVID-19.** J Allergy Clin Immunol 2020; Bradding P, Richardson M, Hinks TSC *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450087>
12. **Molecular Docking, Simulation and MM-PBSA Studies of Nigella Sativa Compounds: A Computational Quest to identify Potential Natural Antiviral for COVID-19 Treatment.** *J Biomol Struct Dyn* 2020:1-16Ahmad S, Abbasi HW, Shahid S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462996>
 13. **Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs.** *J Biomol Struct Dyn* 2020:1-11Amin M, Abbas G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469265>
 14. **Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease.** *J Biomol Struct Dyn* 2020:1-15Choudhury C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452282>
 15. **Withanone and withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.** *J Biomol Struct Dyn* 2020:1-27Kumar V, Dhanjal JK, Bhargava P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469279>
 16. **Early Phylogenetic Diversification of SARS-CoV-2: Determination of Variants and the Effect on Epidemiology, Immunology, and Diagnostics.** *J Clin Med* 2020; 9Kaden R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466577>
 17. **Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.** *Life Sci* 2020:117842Banerjee A, Czinn SJ, Reiter RJ, Blanchard TG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454157>
 18. **Novel Immunoglobulin Domain Proteins Provide Insights into Evolution and Pathogenesis of SARS-CoV-2-Related Viruses.** *mBio* 2020; 11Tan Y, Schneider T, Leong M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471829>
 19. **Why have nanotechnologies been underutilized in the global uprising against the coronavirus pandemic?** *Nanomedicine (Lond)* 2020; Uskokovic V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462968>
 20. **Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.** *Naunyn Schmiedeberg Arch. Pharmacol.* 2020; Rizzo E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462282>
 21. **Excess Ascorbate is a Chemical Stress Agent against Proteins and Cells.** *Pharmaceuticals (Basel)* 2020; 13Lehene M, Fischer-Fodor E, Scurtu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471171>
 22. **Shortlisting SARS-CoV-2 Peptides for Targeted Studies from Experimental Data-Dependent Acquisition Tandem Mass Spectrometry Data.** *Proteomics* 2020:e2000107Gouveia D, Grenga L, Gaillard JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462744>
 23. **Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.** *Viruses* 2020; 12Younes N, Al-Sadeq DW, Al-Jighefee H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466458>

Biomarkers - Genetics (53 articles)

1. **Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2.** *Am J Clin Pathol* 2020; Cradic K, Lockhart M, Ozbolt P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462195>
2. **Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department.** *Am J Emerg Med* 2020; Waltuch T, Gill P, Zinns LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471782>
3. **SARS-CoV-2 Presence in seminal fluid: myth or reality.** *Andrology* 2020; Paoli D, Pallotti F, Turriziani O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453494>
4. **Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.** *Arch Med Res* 2020; Assandri R, Buscarini E, Canetta C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471703>
5. **Rapid and robust bioanalytical assays are critical for SARS-CoV-2 therapeutic and vaccine development and beyond.** *Bioanalysis* 2020; Kar S, Islam R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453605>
6. **Clinical Significance of Blue-Green Neutrophil and Monocyte Cytoplasmic Inclusions in SARS-CoV-2 Positive Critically Ill Patients.** *Br. J. Haematol.* 2020; Cantu MD, Towne WS, Emmons FN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453859>
7. **Delayed-Phase Thrombocytopenia in Patients of Coronavirus Disease 2019 (COVID-19).** *Br. J. Haematol.* 2020; Chen W, Li Z, Yang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453877>
8. **Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.** *Cell* 2020; Grifoni A, Weiskopf D, Ramirez SI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473127>
9. **Lymphopenia in COVID-19: Therapeutic Opportunities.** *Cell Biol. Int.* 2020; Fathi N, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458561>
10. **Diagnostic performance of a SARS-CoV-2 IgG/IgM lateral flow immunochromatography assay in symptomatic patients presenting to the emergency department.** *Clin Chem Lab Med* 2020; Bernasconi L, Oberle M, Gislser V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459191>
11. **Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence.** *Clin Chem Lab Med* 2020; Bohn MK, Lippi G, Horvath A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459192>
12. **Low levels of total and ionized calcium in blood of COVID-19 patients.** *Clin Chem Lab Med* 2020; Cappellini F, Brivio R, Casati M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459190>
13. **Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody.** *Clin Chem Lab Med* 2020; Tre-Hardy M, Wilmet A, Beukinga I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447328>
14. **An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19.** *Clin Chim Acta* 2020; Saadat M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454047>
15. **Detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human breast milk of a mildly symptomatic patient with coronavirus disease 2019 (COVID-19).** *Clin Infect Dis* 2020; Tam PCK, Ly KM, Kernich ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472683>
16. **Metatranscriptomic Characterization of COVID-19 Identified A Host Transcriptional Classifier Associated With Immune Signaling.** *Clin Infect Dis* 2020; Zhang H, Ai JW, Yang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463434>

17. **The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis.** *Crit Care* 2020; 24:255Aziz M, Fatima R, Lee-Smith W, Assaly R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456658>
18. **COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.** *Crit Care* 2020; 24:263Kox M, Frenzel T, Schouten J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456696>
19. **Duration of SARS-CoV-2 viral RNA in asymptomatic carriers.** *Crit Care* 2020; 24:245Yan X, Han X, Fan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448332>
20. **Two False Negative Test Results in a Symptomatic Patient with a Confirmed Case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).** *Cureus* 2020; 12:e8198Lagziel T, Quiroga L, Ramos M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455090>
21. **The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.** *Cytokine Growth Factor Rev.* 2020; Coperchini F, Chiovato L, Croce L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446778>
22. **Optimization of the CDC Protocol of Molecular Diagnosis of COVID-19 for Timely Diagnosis.** *Diagnostics (Basel)* 2020; 10Chen CJ, Hsieh LL, Lin SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455796>
23. **Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.** *Electrophoresis* 2020; Scheller C, Krebs F, Minkner R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469436>
24. **Investigation and Serologic Follow-Up of Contacts of Early Confirmed Case-Patient with COVID-19, United States.** *Emerg Infect Dis* 2020; 26Chu VT, Freeman-Ponder B, Lindquist S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470316>
25. **Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2.** *Emerg Microbes Infect* 2020:1-14Chen JH, Yip CC, Poon RW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459137>
26. **The Allplex 2019-nCoV (Seegene) assay: which performances are for SARS-CoV-2 infection diagnosis?** *Eur J Clin Microbiol Infect Dis* 2020; Farfour E, Lesprit P, Visseaux B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462501>
27. **The amount of cytokine-release defines different shades of Sars-Cov2 infection.** *Exp. Biol. Med. (Maywood)* 2020:1535370220928964Bindoli S, Felicetti M, Sfriso P, Doria A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460624>
28. **Nasopharyngeal swab or clinical-radiological evidence: the dark side of the moon for cancer patients in the COVID-19 era.** *Future Oncol* 2020; Veccia A, Kinspergher S, Dipasquale M, Caffo O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452225>
29. **Hospital infection and COVID-19: Do not put all your eggs on the "swab" tests.** *Infect Control Hosp Epidemiol* 2020:1-3Chirico F, Nucera G, Magnavita N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456750>
30. **A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response.** *Int J Infect Dis* 2020; Lin YC, Cheng CY, Cheng-Pin C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470604>
31. **Clinical evaluation of AusDiagnostics SARS-CoV-2 multiplex tandem PCR assay.** *J Clin Virol* 2020; 128:104448Attwood LO, Francis MJ, Hamblin J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460173>
32. **Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?** *J Endocrinol. Invest.* 2020; Berni A, Malandrino D, Parenti G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451971>
33. **Evaluation of a high-speed but low-throughput RT-qPCR system for SARS-CoV-2 detection.** *J Hosp Infect* 2020; Sakai J, Tarumoto N, Orihara Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446722>
34. **Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive.** *J Infect* 2020; Borghetti A, Ciccullo A, Paratore M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473233>
35. **Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva.** *J Korean Med Sci* 2020; 35:e195Yoon JG, Yoon J, Song JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449329>
36. **Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019.** *J Med Virol* 2020; Choe JY, Kim JW, Kwon HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458479>
37. **Clinical features, isolation, and complete genome sequence of severe acute respiratory syndrome coronavirus 2 from the first two patients in Vietnam.** *J Med Virol* 2020; Phan LT, Nguyen TV, Huynh LKT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462705>
38. **Clinical Utility of Buccal Swabs for Sars-Cov-2 Detection in Covid-19-Infected Children.** *J Pediatric Infect Dis Soc* 2020; Kam KQ, Yung CF, Maiwald M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463086>
39. **Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.** *J. Thromb. Thrombolysis* 2020; Artifoni M, Danic G, Gautier G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451823>
40. **The case of Complement activation in COVID-19 multiorgan impact.** *Kidney Int* 2020; Noris M, Benigni A, Remuzzi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461141>
41. **In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.** *Korean J. Intern. Med.* 2020; Kang CK, Seong MW, Choi SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460458>
42. **Immunoinformatic analysis of the SARS-CoV-2 Envelope protein as a strategy to assess cross-protection against COVID-19.** *Microbes Infect* 2020; Tilocca B, Soggiu A, Sanguinetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446902>
43. **Analysis of Mortality in Patients With COVID-19: Clinical and Laboratory Parameters.** *Open Forum Infect Dis* 2020; 7:ofaa152Tian S, Liu H, Liao M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457924>
44. **C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation.** *Open Forum Infect Dis* 2020; 7:ofaa153Wang G, Wu C, Zhang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455147>
45. **Procoagulation, hypercoagulation and fibrinolytic "shut down" detected with ClotPro(R) viscoelastic tests in COVID-19 patients.** *Orv. Hetil.* 2020; 161:899-907Zatroch I, Smudla A, Babik B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453702>

46. **Inappropriate Nasopharyngeal Sampling for SARS-CoV-2 Detection Is a Relevant Cause of False-Negative Reports.** *Otolaryngol Head Neck Surg* 2020;194599820931793Piras A, Rizzo D, Uzzau S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450754>
47. **Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in Japan.** *QJM* 2020; Takita M, Matsumura T, Yamamoto K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32467977>
48. **D-dimer in patients infected with COVID-19 and suspected pulmonary embolism.** *Respir. Med.* 2020; 169:106023Garcia-Olive I, Sintes H, Radua J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454268>
49. **COVID-19 and hypercoagulability in the outpatient setting.** *Thromb Res* 2020; 192:122-123Emert R, Shah P, Zampella JG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473495>
50. **MICROVASCULAR THROMBOSIS: EXPERIMENTAL AND CLINICAL IMPLICATIONS.** *Transl. Res.* 2020; Bray MA, Sartain SA, Gollamudi J, Rumbaut RE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454092>
51. **Association of viral load with serum biomarkers among COVID-19 cases.** *Virology* 2020; 546:122-126Shi F, Wu T, Zhu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452410>
52. **A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions.** *World J. Urol.* 2020; Chan VW, Chiu PK, Yee CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462305>
53. **Antibody tests for COVID-19: What the results tell us.** *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2020; Horvath K, Semlitsch T, Jeitler K *et al.*

Children (20 articles)

1. **Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department.** *Am J Emerg Med* 2020; Waltuch T, Gill P, Zinns LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471782>
2. **Infection control practices in children during COVID-19 pandemic: differences from adults.** *Am. J. Infect. Control* 2020; Devrim I, Bayram N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464297>
3. **Diagnosis of COVID-19 in children: the story evolves.** *BMC Med* 2020; 18:158Harwood R, Sinha I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460871>
4. **Depression and anxiety among adolescents during COVID-19: A cross-sectional study.** *Brain Behav Immun* 2020; Chen F, Zheng D, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464156>
5. **It's True Even in a Pandemic: Children are Not Merely Little Adults.** *Clin Infect Dis* 2020; Creech CB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472937>
6. **Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.** *Clin Infect Dis* 2020; Raabe VN, Lighter J, Caplan AL, Ratner AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459832>
7. **Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).** *Clin. Transl. Oncol.* 2020; Rubio-San-Simon A, Verdu-Amoros J, Hladun R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472454>
8. **Cutaneous manifestations in COVID-19: a skin rash in a child.** *Dermatol Ther* 2020:e13712Olisova OY, Anpilogova EM, Shnakhova LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472593>
9. **Compliance and Psychological Impact of Quarantine in Children and Adolescents due to Covid-19 Pandemic.** *Indian J Pediatr* 2020; Saurabh K, Ranjan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472347>
10. **COVID-19 Disease in Children: What Dentists Should Know and Do to Prevent Viral Spread. The Italian Point of View.** *Int J Environ Res Public Health* 2020; 17Ferrazzano GF, Ingenito A, Cantile T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455859>
11. **Staying home during "COVID-19" decreased fractures, but trauma did not quarantine in one hundred and twelve adults and twenty eight children and the "tsunami of recommendations" could not lockdown twelve elective operations.** *Int. Orthop.* 2020; Hernigou J, Morel X, Callewier A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451655>
12. **Italian pediatric respiratory society recommendations on pediatric pulmonary function testing during COVID-19 pandemic.** *Ital. J. Pediatr.* 2020; 46:68Bignamini E, Cazzato S, Cutrera R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448282>
13. **Challenges in the Care of Children and Youth With Diabetes in Times of the Corona Pandemic: Personal View of the Situation in a German Clinic.** *J. Diabetes Sci. Technol.* 2020;1932296820930281 Ziegler R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468840>
14. **Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children.** *J Eur Acad Dermatol Venereol* 2020; Labe P, Ly A, Sin C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455505>
15. **Higher prevalence of asymptomatic or mild COVID-19 in children, claims and clues.** *J Med Virol* 2020; Miri SM, Noorbakhsh F, Mohebbi SR, Ghaemi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470174>
16. **Intubation precautions in a pediatric patient with severe COVID-19.** *J Pediatr Surg Case Rep* 2020; 58:101495Shaw R, Tighe N, Odegard KC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455111>
17. **Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series.** *J Pediatric Infect Dis Soc* 2020; Chiotos K, Bassiri H, Behrens EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463092>
18. **Projecting the impact of COVID-19 pandemic on childhood obesity in the U.S.: A microsimulation model.** *J Sport Health Sci* 2020; An R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454174>
19. **African American children are at higher risk for COVID-19 infection.** *Pediatr. Allergy Immunol.* 2020; Bandi S, Nevid MZ, Mahdavinia M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469426>
20. **[Coronavirus Covid-19 infection and breastfeeding: an exploratory review].** *Rev. Esp. Salud Publica* 2020; 94Fernandez-Carrasco FJ, Vazquez-Lara JM, Gonzalez-Mey U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458823>

Clinical Features (17 articles)

1. **Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19.** *Am J Emerg Med* 2020; Wilkerson RG, Adler JD, Shah NG, Brown R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471783>
2. **Cutaneous hyperesthesia: a novel manifestation of COVID-19.** *Brain Behav Immun* 2020; Krajewski PK, Szepietowski JC, Maj J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464157>
3. **"COVID-Mask": an atypical livedoid manifestation of COVID-19 observed in a northern Italy hospital.** *Dermatol Ther* 2020:e13701 Conforti C, Zalaudek I, Giuffrida R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472566>
4. **Cutaneous manifestations of COVID-19: A review of the published literature.** *Dermatol Ther* 2020; Elmas OF, Demirbas A, Ozyurt K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458546>
5. **Cutaneous manifestations in COVID-19: a skin rash in a child.** *Dermatol Ther* 2020:e13712 Olisova OY, Anpilogova EM, Shnakhova LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472593>
6. **Dysphagia in COVID-19 -multilevel damage to the swallowing network?** *Eur. J. Neurol.* 2020; Dziewas R, Warnecke T, Zurcher P, Schefold JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460415>
7. **Extra-respiratory manifestations of COVID-19.** *Int J Antimicrob Agents* 2020:106024 Lai CC, Ko WC, Lee PI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450197>
8. **Acral findings during the COVID-19 outbreak: Chilblain-like lesions should be preferred to acro- ischemic lesions.** *J Am Acad Dermatol* 2020; Piccolo V, Bassi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446827>
9. **Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients - the "Gabrin sign".** *J Am Acad Dermatol* 2020; Wambier CG, Vano-Galvan S, McCoy J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446821>
10. **The Ocular Manifestations and Transmission of COVID-19: Recommendations for Prevention.** *J. Emerg. Med.* 2020; Dockery DM, Rowe SG, Murphy MA, Krzystolik MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456959>
11. **Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review.** *J Eur Acad Dermatol Venereol* 2020; Docampo-Simon A, Sanchez-Pujol MJ, Juan-Carpena G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452545>
12. **COVID-19 Presenting with Atypical Sweet's Syndrome.** *J Eur Acad Dermatol Venereol* 2020; Taskin B, Vural S, Altug E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452542>
13. **The Association between Laryngopharyngeal Reflux and COVID-19 is still not Demonstrated.** *J Med Virol* 2020; Lechien JR, Bartaire E, Bobin F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462666>
14. **A retrospective study of the initial 25 COVID-19 patients in Luoyang, China.** *Jpn J Radiol* 2020; Duan X, Guo X, Qiang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458125>
15. **Oncologic patient with COVID-19 discovered incidentally by PET/CT examination: (A COVID-19-pandemia orvosszakmai kerdesei).** *Orv. Hetil.* 2020; 161:971-976 Czibor S, Kristof E, Kecskes K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453695>
16. **Chilblains-like lesions and COVID-19.** *Pediatr. Dermatol.* 2020; Joob B, Wiwanitkit V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453902>
17. **[Clinical feature changes of a COVID-19 patient from mild to critical condition and cardiopulmonary pathological results].** *Zhonghua Xin Xue Guan Bing Za Zhi* 2020; 48:E018 Jiang SW, Gao H, Wu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455515>

CNS (29 articles)

1. **Heralding Healthcare Professionals: Recognition of Neurological Deficits in COVID-19.** *ACS Chem Neurosci* 2020; Baig AM, Sanders EC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469504>
2. **Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology.** *Acta Neuropathol.* 2020; Reichard RR, Kashani KB, Boire NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449057>
3. **Olfactory dysfunction in COVID-19, a review of the evidence and implications for pandemic management.** *Acta Otorrinolaringol. Esp.* 2020; Lop Gros J, Iglesias Coma M, Gonzalez Farre M, Serra Pujadas C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466862>
4. **Loss of Smell and Taste in 2013 European Patients With Mild to Moderate COVID-19.** *Ann Intern Med* 2020; Lechien JR, Chiesa-Estomba CM, Hans S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449883>
5. **Cutaneous hyperesthesia: a novel manifestation of COVID-19.** *Brain Behav Immun* 2020; Krajewski PK, Szepietowski JC, Maj J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464157>
6. **Anosmia in COVID-19 patients.** *Clin Microbiol Infect* 2020; Hornuss D, Lange B, Schroter N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447049>
7. **A Review of Neurological Complications of COVID-19.** *Cureus* 2020; 12:e8192 Sheraton M, Deo N, Kashyap R, Surani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455089>
8. **Psychophysical Olfactory Tests and Detection of COVID-19 in Patients With Sudden Onset Olfactory Dysfunction: A Prospective Study.** *Ear Nose Throat J* 2020:145561320929169 Lechien JR, Cabaraux P, Chiesa-Estomba CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469246>
9. **New onset of loss of smell or taste in household contacts of home-isolated SARS-CoV-2-positive subjects.** *Eur Arch Otorhinolaryngol* 2020; Boscolo-Rizzo P, Borsetto D, Spinato G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449021>
10. **The role of self-reported smell and taste disorders in suspected COVID19.** *Eur Arch Otorhinolaryngol* 2020; Printza A, Constantinidis J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447496>
11. **COVID-19 and herpes zoster co-infection presenting with trigeminal neuropathy.** *Eur. J. Neurol.* 2020; de Freitas Ferreira ACA, Romao TT, Y SIM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449248>
12. **Dysphagia in COVID-19 -multilevel damage to the swallowing network?** *Eur. J. Neurol.* 2020; Dziewas R, Warnecke T, Zurcher P, Schefold JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460415>
13. **Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection.** *Exp. Mol. Pathol.* 2020:104474 Lavi E, Cong L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454103>
14. **Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement.** *Gen. Hosp. Psychiatry* 2020; 65:47-53 Beach SR, Praschan NC, Hogan C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470824>

15. **Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.** J. Cardiovasc. Transl. Res. 2020; Fudim M, Qadri YJ, Ghadimi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458400>
16. **SARS-CoV-2 Infection Leads to Neurological Dysfunction.** J. Neuroimmune Pharmacol. 2020; Acharya A, Kevadiya BD, Gendelman HE, Byrareddy SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447746>
17. **Neurological manifestations of COVID-19: a review of what we know so far.** J. Neurol. 2020; Gklinos P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458197>
18. **Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms.** J. Neurol. 2020; Zhou Z, Kang H, Li S, Zhao X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458193>
19. **COVID-19 related neuroimaging findings: A signal of thromboembolic complications and a strong prognostic marker of poor patient outcome.** J Neurol Sci 2020; 414:116923Jain R, Young M, Dogra S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447193>
20. **The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries.** J Neurol Sci 2020; 414:116884Roman GC, Spencer PS, Reis J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464367>
21. **COVID-19 and the nervous system.** J. Neurovirol. 2020; Berger JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447630>
22. **Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study.** Mov Disord 2020; Cilia R, Bonvegna S, Straccia G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449528>
23. **Olfactory dysfunction in recovered COVID-19 patients.** Mov Disord 2020; Li J, Long X, Zhu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468632>
24. **Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical - Paraclinical follow up study of a case.** Mult Scler Relat Disord 2020; 43:102216Afshar H, Yassin Z, Kalantari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464585>
25. **Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.** Mult Scler Relat Disord 2020; 43:102222Ghajarzadeh M, Mirmosayyeb O, Barzegar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464586>
26. **Brainstem involvement and respiratory failure in COVID-19.** Neurol Sci 2020; Manganelli F, Vargas M, Iovino A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472516>
27. **The involvement of the central nervous system in patients with COVID-19.** Rev Neurosci. 2020; Saleki K, Banazadeh M, Saghadzadeh A, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463395>
28. **Treatment of Acute Ischemic Stroke due to Large Vessel Occlusion With COVID-19: Experience From Paris.** Stroke 2020;Strokeaha120030574Escalard S, Maier B, Redjem H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466736>
29. **Impact of COVID-19 on an Academic Neurosurgery Department: The Johns Hopkins Experience.** World Neurosurg 2020; Khalafallah AM, Jimenez AE, Lee RP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461176>

Complications (57 articles)

1. **A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois.** AIDS Patient Care STDS 2020; Ridgway JP, Farley B, Benoit JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469614>
2. **Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department.** Am J Emerg Med 2020; Waltuch T, Gill P, Zinns LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471782>
3. **Early COVID-19 infection after lung transplantation.** Am J Transplant 2020; Keller BC, Le A, Sobhanie M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471004>
4. **It is currently unknown whether SARS-CoV-2 is viable in semen or whether COVID-19 damages sperm.** Andrology 2020; Perry MJ, Arrington S, Neumann LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471002>
5. **Is molecular mimicry the culprit in the autoimmune hemolytic anemia affecting COVID-19 patients?** Br. J. Haematol. 2020; Angileri F, Legare S, Marino Gammazza A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453861>
6. **Delayed-Phase Thrombocytopenia in Patients of Coronavirus Disease 2019 (COVID-19).** Br. J. Haematol. 2020; Chen W, Li Z, Yang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453877>
7. **Anti-NMDA Receptor Encephalitis in a Psychiatric Covid-19 Patient: a Case Report.** Brain Behav Immun 2020; Panariello A, Bassetti R, Radice A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454137>
8. **COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area.** Breast Cancer Res. 2020; 22:55Vuagnat P, Frelaut M, Ramtohl T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460829>
9. **Treating the SARS-CoV-2-positive patient with cancer: A proposal for a pragmatic and transparent ethical process.** Cancer 2020; Perni S, Milligan MG, Saraf A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463478>
10. **Need for Objective Assessment of Volume Status in Critically Ill Patients with COVID-19: The Tri-POCUS Approach.** Cardiorenal Med. 2020;1-8Koratala A, Ronco C, Kazory A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460302>
11. **Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.** Clin Rheumatol 2020; Dai J, Xiong Y, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451729>
12. **COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.** Crit Care 2020; 24:263Kox M, Frenzel T, Schouten J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456696>
13. **Two False Negative Test Results in a Symptomatic Patient with a Confirmed Case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected Stevens-Johnson**

- Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).** *Cureus* 2020; 12:e8198Lagziel T, Quiroga L, Ramos M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455090>
14. **The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.** *Cytokine Growth Factor Rev.* 2020; Coperchini F, Chiovato L, Croce L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446778>
 15. **Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).** *Dermatol Ther (Heidelb)* 2020; Brownstone ND, Thibodeaux QG, Reddy VD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468230>
 16. **Jointly providing for severe COVID-19 cases: Interview with a hospital pharmacist.** *Deutsche Apotheker Zeitung* 2020; 60Dedy J.
 17. **COVID-19 Triage: Who is an inpatient? The Essen triage model.** *Deutsche medizinische Wochenschrift (1946)* 2020; Fistera D, Risse J, Manegold R *et al.*
 18. **SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19?** *EMBO Mol Med* 2020; Bengoechea JA, Bamford CGG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453917>
 19. **Informing Emergency Care for all patients: The Registry for Emergency Care (REC) Project Protocol.** *Emerg. Med. Australas.* 2020; O'Reilly GM, Mitchell RD, Mitra B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462732>
 20. **Indications and timing for tracheostomy in patients with SARS CoV2-related.** *Eur Arch Otorhinolaryngol* 2020; Ferri E, Boscolo Nata F, Pedruzzi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458121>
 21. **Excess out-of-hospital deaths during COVID-19 outbreak: evidence of pulmonary embolism as a main determinant.** *Eur J Heart Fail* 2020; Benzakoun J, Hmeydia G, Delabarde T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463538>
 22. **COVID-19 and herpes zoster co-infection presenting with trigeminal neuropathy.** *Eur. J. Neurol.* 2020; de Freitas Ferreira ACA, Romao TT, Y SIM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449248>
 23. **Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection.** *Exp. Mol. Pathol.* 2020:104474Lavi E, Cong L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454103>
 24. **Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?** *Future Oncol* 2020; Hays P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456461>
 25. **Does SARS-CoV-2 infection cause chronic neurological complications?** *Geroscience* 2020; Hascup ER, Hascup KN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451846>
 26. **Multisystem Inflammatory Syndrome with Features of Atypical Kawasaki Disease during COVID-19 Pandemic.** *Indian J Pediatr* 2020; Rauf A, Vijayan A, John ST *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462354>
 27. **Bowel perforation in a Covid-19 patient: case report.** *Int. J. Colorectal Dis.* 2020; De Nardi P, Parolini DC, Ripa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458395>
 28. **Unheralded Lower Limb Threatening Ischemia in a COVID-19 Patient.** *Int J Infect Dis* 2020; Andrea V, Gianluca F, Rodolfo P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447121>
 29. **Clinical Characteristics of Critically Ill Patients Co-infected with SARS-CoV-2 and the Influenza Virus in Wuhan, China.** *Int J Infect Dis* 2020; Ma S, Lai X, Chen Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470606>
 30. **Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis.** *Int J Public Health* 2020; Jain V, Yuan JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451563>
 31. **Covid-19 induced superimposed bacterial infection.** *J Biomol Struct Dyn* 2020:1-10Hendaus MA, Jomha FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448041>
 32. **The COVID-19 Infection in Italy: A Statistical Study of an Abnormally Severe Disease.** *J Clin Med* 2020; 9De Natale G, Ricciardi V, De Luca G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455807>
 33. **Community-acquired viral respiratory infections amongst hospitalized inpatients during a COVID-19 outbreak in Singapore: co-infection and clinical outcomes.** *J Clin Virol* 2020; 128:104436Wee LE, Ko KKK, Ho WQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447256>
 34. **Late onset of acral necrosis after SARS-CoV-2 infection resolution.** *J Eur Acad Dermatol Venereol* 2020; Balestri R, Termine S, Rech G, Girardelli CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455499>
 35. **Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children.** *J Eur Acad Dermatol Venereol* 2020; Labe P, Ly A, Sin C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455505>
 36. **A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics. Severe Cutaneous Adverse Reactions (SCARs) are an issue.** *J Eur Acad Dermatol Venereol* 2020; Torres-Navarro I, Abril-Perez C, Roca-Gines J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455478>
 37. **The Novel Coronavirus Disease (COVID-19) Complicated by Pulmonary Embolism and Acute Respiratory Distress Syndrome.** *J Med Virol* 2020; Li T, Cheng GS, Pipavath S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470156>
 38. **Letter to the Editor: Are severe COVID-19 patients more susceptible to conjunctivitis?** *J Med Virol* 2020; Liu M, Dai C, Lv X, Li B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470212>
 39. **Clinical features and outcome of HIV/SARS-CoV-2 co-infected patients in the Bronx, New York City.** *J Med Virol* 2020; Suwanwongse K, Shabarek N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462663>
 40. **COVID-19 related neuroimaging findings: A signal of thromboembolic complications and a strong prognostic marker of poor patient outcome.** *J Neurol Sci* 2020; 414:116923Jain R, Young M, Dogra S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447193>
 41. **Intubation precautions in a pediatric patient with severe COVID-19.** *J Pediatr Surg Case Rep* 2020; 58:101495Shaw R, Tighe N, Odegard KC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455111>
 42. **Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.** *J. Thromb. Thrombolysis* 2020; Artifoni M, Danic G, Gautier G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451823>
 43. **Management of Upper Airway Bleeding in COVID-19 Patients on Extracorporeal Membrane Oxygenation.** *Laryngoscope* 2020; LoSavio PS, Patel T, Urban MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470179>

44. **Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review.** *Life Sci* 2020; 255:117839 Renu K, Prasanna PL, Valsala Gopalakrishnan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450165>
45. **Brainstem involvement and respiratory failure in COVID-19.** *Neurol Sci* 2020; Manganelli F, Vargas M, Iovino A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472516>
46. **Procoagulation, hypercoagulation and fibrinolytic "shut down" detected with ClotPro(R) viscoelastic tests in COVID-19 patients.** *Orv. Hetil.* 2020; 161:899-907 Zatroch I, Smudla A, Babik B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453702>
47. **Safety and Prognosis in Percutaneous vs Surgical Tracheostomy in 27 Patients With COVID-19.** *Otolaryngol Head Neck Surg* 2020:194599820931801 Riestra-Ayora J, Yanes-Diaz J, Penuelas O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450761>
48. **COVID-19: Komorbiditäten prädisponieren für schweren Verlauf.** *Pneumologie* 2020; 74:257 Franke K.
49. **Prone positioning to improve oxygenation and relieve respiratory symptoms in awake, spontaneously breathing non-intubated patients with COVID-19 pneumonia.** *Respir Med Case Rep* 2020; 30:101096 Sztajn bok J, Maselli-Schoueri JH, Cunha de Resende Brasil LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455107>
50. **COVID-19 and hypercoagulability in the outpatient setting.** *Thromb Res* 2020; 192:122-123 Emert R, Shah P, Zampella JG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473495>
51. **MICROVASCULAR THROMBOSIS: EXPERIMENTAL AND CLINICAL IMPLICATIONS.** *Transl. Res.* 2020; Bray MA, Sartain SA, Gollamudi J, Rumbaut RE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454092>
52. **COVID-19 in an HIV-positive Kidney Transplant Recipient.** *Transpl Infect Dis* 2020:e13338 Kumar RN, Tanna SD, Shetty AA, Stosor V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453483>
53. **Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab.** *Transpl Infect Dis* 2020:e13334 Lauterio A, Valsecchi M, Santambrogio S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449235>
54. **Covid-19 in solid organ transplant recipients: A single center experience.** *Transpl Int* 2020; Hoek RAS, Manintveld OC, Betjes MGH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460390>
55. **Prevention of thrombosis in pregnant women with suspected SARS-CoV-2 infection: clinical management algorithm.** *Ultrasound Obstet Gynecol* 2020; Lou-Mercade AC, Gavin O, Oros D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449242>
56. **Liver injury in COVID-19: The current evidence.** *United European Gastroenterol J* 2020; 8:509-519 Alqahtani SA, Schattenberg JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450787>
57. **COVID-19 complicated by pulmonary embolism treated with catheter directed thrombectomy.** *Vasa* 2020:1-5 Galastri FL, Valle LGM, Affonso BB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462990>

Cured – Recovered (5 articles)

1. **The COVID-19 Rehabilitation Pandemic.** *Age Ageing* 2020; De Biase S, Cook L, Skelton DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470131>
2. **COVID-19: The road to recovery.** *Am. J. Surg.* 2020; Diaz A, Rahmanian A, Pawlik TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446466>
3. **Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis.** *J Rehabil Med* 2020; Ahmed H, Patel K, Greenwood DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449782>
4. **Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.** *Mult Scler Relat Disord* 2020; 43:102222 Ghajarzadeh M, Mirmosayyeb O, Barzegar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464586>
5. **The pulmonary sequelae in discharged patients with COVID-19: a short-term observational study.** *Respir Res* 2020; 21:125 Liu D, Zhang W, Pan F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448391>

Cardiovascular disease (34 articles)

1. **An update on ACE2 amplification and its therapeutic potential.** *Acta Physiol. (Oxf.)* 2020:e13513 Marquez A, Wysocki J, Pandit J, Batlle D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469114>
2. **Interpretation of arrhythmogenic effects of COVID-19 disease through ECG.** *Aging Male* 2020:1-4 Ozturk F, Karaduman M, Coldur R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449420>
3. **Management of heart transplant candidates in the time of COVID-19 pandemic: looking for answers.** *Am J Transplant* 2020; Pascale R, Trapani F, Potena L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470181>
4. **Surveillance for COVID-19 in cardiac inpatients: containing COVID-19 in a specialised cardiac centre.** *Can J Cardiol* 2020; Wee LE, Wen R, Jean Sim XY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473301>
5. **STEMI during the COVID-19 Pandemic - An Evaluation of Incidence.** *Cardiovasc. Pathol.* 2020; 48:107232 Zitelny E, Newman N, Zhao D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454398>
6. **Decreased myocardial infarction admissions during COVID times: what can we learn?** *Cardiovasc Res* 2020; Niccoli G, Luescher TF, Crea F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463078>
7. **Treatment of ST-segment elevation myocardial infarction during COVID-19 pandemic.** *Cardiovasc. Revasc. Med.* 2020; Yerasi C, Case BC, Forrestal BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471712>
8. **The Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19) - a Systematic Echocardiographic Study.** *Circulation* 2020; Szekeley Y, Lichter Y, Taieb P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469253>

9. **Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.** *Clin Res Cardiol* 2020; Bohm M, Frey N, Giannitsis E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462267>
10. **Clinical analysis of sinus bradycardia in patients with severe COVID-19 pneumonia.** *Crit Care* 2020; 24:257Hu L, Gong L, Jiang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456695>
11. **The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population.** *Curr. Oncol. Rep.* 2020; 22:60Asokan I, Rabadia SV, Yang EH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462289>
12. **Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:682-686Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F.
13. **Rapid guide to the management of cardiac patients during the COVID-19 pandemic in Egypt: "a position statement of the Egyptian Society of Cardiology".** *Egypt Heart J* 2020; 72:30Shaheen S, Awwad O, Shokry K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462497>
14. **Acute Cerebral Stroke with Multiple Infarctions and COVID-19, France, 2020.** *Emerg Infect Dis* 2020; 26Zayet S, Klopfenstein T, Kovacs R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453685>
15. **Admission of patients with STEMI since the outbreak of the COVID-19 pandemic. A survey by the European Society of Cardiology.** *Eur Heart J Qual Care Clin Outcomes* 2020; Pessoa-Amorim G, Camm CF, Gajendragadkar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32467968>
16. **Heart failure management during COVID-19 outbreak in Italy. Telemedicine experience from a heart failure university tertiary referral centre.** *Eur J Heart Fail* 2020; Salzano A, D'Assante R, Stagnaro FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463534>
17. **Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.** *Eur J Heart Fail* 2020; Zhang Y, Stewart Coats AJ, Zheng Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463543>
18. **Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia during the COVID-19 Pandemic: A Living Document.** *Heart Lung Circ.* 2020; Kumar S, Haqqani H, Wynn G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451232>
19. **Multisystem Inflammatory Syndrome with Features of Atypical Kawasaki Disease during COVID-19 Pandemic.** *Indian J Pediatr* 2020; Rauf A, Vijayan A, John ST *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462354>
20. **ACE2, TMPRSS2 AND FURIN GENE EXPRESSION IN THE AIRWAYS OF PEOPLE WITH ASTHMA - IMPLICATIONS FOR COVID-19.** *J Allergy Clin Immunol* 2020; Bradding P, Richardson M, Hinks TSC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450087>
21. **Declines in Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic: A Multicenter Tertiary Care Experience.** *J Am Coll Cardiol* 2020; Bhatt AS, Moscone A, McElrath EE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470516>
22. **Transcatheter Aortic Valve Replacement in the Coronavirus Disease 2019 (COVID-19) Era.** *J Am Heart Assoc* 2020:e017121Mentias A, Jneid H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452247>
23. **Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring.** *J Am Heart Assoc* 2020:e017144Ramireddy A, Chugh H, Reinier K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463348>
24. **COVID-19 and Renin-Angiotensin system inhibition - role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?** *J Intern Med* 2020; Aleksova A, Ferro F, Gagno G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459372>
25. **Rhythm blues in the time of coronavirus disease 2019 (COVID-19): how the cardiac electrophysiologist adapts to a viral pandemic in Singapore.** *J. Interv. Card. Electrophysiol.* 2020; Chia PL, Tan K, Tan LW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458182>
26. **Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure".** *mBio* 2020; 11Fedson DS, Opal SM, Rordam OM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471831>
27. **Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.** *Med. Hypotheses* 2020; 143:109859Ponti G, Ruini C, Tomasi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464494>
28. **Ischaemic stroke and SARS-CoV-2 infection: A causal or incidental association?** *Neurologia* 2020; Barrios-Lopez JM, Rego-Garcia I, Munoz Martinez C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448674>
29. **Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.** *Nutr. Metab. Cardiovasc. Dis.* 2020; Li M, Dong Y, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456948>
30. **D-dimer in patients infected with COVID-19 and suspected pulmonary embolism.** *Respir. Med.* 2020; 169:106023Garcia-Olive I, Sintes H, Radua J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454268>
31. **[COVID-19 and cardiovascular and kidney disease: Where are we? Where are we going?].** *Semerger* 2020; Pallares Carratala V, Gorriz-Zambrano C, Morillas Arino C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448633>
32. **Treatment of Acute Ischemic Stroke due to Large Vessel Occlusion With COVID-19: Experience From Paris.** *Stroke* 2020:Strokeaha120030574Escalard S, Maier B, Redjem H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466736>
33. **Clinical Characteristics and Outcomes of COVID-19 Patients With a History of Stroke in Wuhan, China.** *Stroke* 2020:Strokeaha120030365Qin C, Zhou L, Hu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466735>
34. **COVID-19 complicated by pulmonary embolism treated with catheter directed thrombectomy.** *Vasa* 2020:1-5Galastri FL, Valle LGM, Affonso BB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462990>

Diagnosis (4 articles)

1. **Diagnosis of COVID-19 in children: the story evolves.** *BMC Med* 2020; 18:158Harwood R, Sinha I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460871>

2. **Psychophysical Olfactory Tests and Detection of COVID-19 in Patients With Sudden Onset Olfactory Dysfunction: A Prospective Study.** *Ear Nose Throat J* 2020;145561320929169Lechien JR, Cabaraux P, Chiesa-Estomba CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469246>
3. **The outlook for diagnostic purposes of the 2019-novel coronavirus disease.** *J. Cell. Physiol.* 2020; Tahmasebi S, Khosh E, Esmaeilzadeh A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452050>
4. **Role of biological Data Mining and Machine Learning Techniques in Detecting and Diagnosing the Novel Coronavirus (COVID-19): A Systematic Review.** *J Med Syst* 2020; 44:122Albahri AS, Hamid RA, Alwan JK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451808>

DM-MS-Obesity (27 articles)

1. **Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.** *Aging (Albany NY)* 2020; 12Menendez JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463794>
2. **Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes.** *Am J Physiol Endocrinol Metab* 2020; Korakas E, Ikonomidis I, Kousathana F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459524>
3. **A new diagnostic strategy for gestational diabetes during the COVID-19 pandemic for the Japanese population.** *Diabetes Metab Res Rev* 2020:e3351Kasuga Y, Saisho Y, Ikenoue S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453497>
4. **SARS-CoV-2 and Diabetes: New Challenges for the Disease.** *Diabetes Res Clin Pract* 2020:108228Cristelo C, Azevedo C, Moreira Marques J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446801>
5. **Association of Diabetes Mellitus with Disease Severity and Prognosis in COVID-19: A Retrospective Cohort Study.** *Diabetes Res Clin Pract* 2020:108227Zhang Y, Cui Y, Shen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446795>
6. **Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends.** *Diabetes Ther.* 2020; Bossi AC, Forloni F, Colombelli PL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447736>
7. **Diabetes and pregnancy—update 2020.** *Diabetologie* 2020; Kleinwechter H.
8. **Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.** *Diabetologia* 2020; Cariou B, Hadjadj S, Wargny M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472191>
9. **Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.** *Int J Environ Res Public Health* 2020; 17Mirabelli M, Chiefari E, Puccio L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456064>
10. **COVID-19 and diabetes: Is there enough evidence?** *J. Clin. Hypertens. (Greenwich)* 2020; Tadic M, Cuspidi C, Sala C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472662>
11. **Comment on "Is the type of diabetes treatment relevant to outcome of COVID-19?".** *J. Diabetes* 2020; Pal R, Banerjee M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459882>
12. **The COVID-19 Pandemic Revealed the Importance and Shortcomings of Technologies for Diabetes Support.** *J. Diabetes Sci. Technol.* 2020:1932296820929721Arsand E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460550>
13. **Relative Limited Impact of COVID-19 on Diabetes: A Personal View.** *J. Diabetes Sci. Technol.* 2020:1932296820930270de Galan BE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468834>
14. **The Time of Uncertainty in Poland.** *J. Diabetes Sci. Technol.* 2020:1932296820931485Dzida GJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460551>
15. **Personal Experience With COVID-19 and Community Screening of Diabetic Retinopathy in Iran.** *J. Diabetes Sci. Technol.* 2020:1932296820930045Jamali S, Ashrafi E, Mohammadi SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460540>
16. **Benefits of Technology in the Age of COVID-19 and Diabetes. . Mobile Phones From a Rwanda Perspective.** *J. Diabetes Sci. Technol.* 2020:1932296820930032Krisiunas E, Sibomana L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460536>
17. **Diabetes Care at the Times of Transition and COVID-19 Pandemics (Ukrainian Experience).** *J. Diabetes Sci. Technol.* 2020:1932296820930031Mankovsky B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468843>
18. **Personal Experiences With COVID-19 and Diabetes Technology: All for Technology Yet Not Technology for All.** *J. Diabetes Sci. Technol.* 2020:1932296820930005Monaghan M, Marks B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460543>
19. **Diabetes and Technology in the Covid-19 Pandemic Crisis.** *J. Diabetes Sci. Technol.* 2020:1932296820929385Spanakis EK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460544>
20. **Would You Believe? A Virus Changes Diabetes Care.** *J. Diabetes Sci. Technol.* 2020:1932296820929381Tack CCJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460553>
21. **COVID-19, Type 1 Diabetes Clinical Practice, Research, and Remote Medical Care: A View From the Land Down-Under.** *J. Diabetes Sci. Technol.* 2020:1932296820929708Venkatesh N, Paldus B, Lee MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468858>
22. **Challenges in the Care of Children and Youth With Diabetes in Times of the Corona Pandemic: Personal View of the Situation in a German Clinic.** *J. Diabetes Sci. Technol.* 2020:1932296820930281Ziegler R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468840>
23. **Self-quarantine and weight gain related risk factors during the COVID-19 pandemic.** *Obes. Res. Clin. Pract.* 2020; Zachary Z, Brianna F, Brianna L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460966>
24. **Possible Role of Adipose Tissue and Endocannabinoid System in COVID-19 Pathogenesis: Can Rimonabant Return?** *Obesity (Silver Spring)* 2020; Briand-Mesange F, Trudel S, Salles J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463562>
25. **Obesity and COVID-19: an Italian snapshot.** *Obesity (Silver Spring)* 2020; Busetto L, Bettini S, Fabris R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463545>
26. **Obesity is associated with worse outcomes in COVID-19: Analysis of Early Data From New York City.** *Obesity (Silver Spring)* 2020; Hajifathalian K, Kumar S, Newberry C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470210>

27. **Diabetes and COVID-19. Therapie** 2020; Bouhanick B, Cracowski JL, Faillie JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471607>

Education and training and science (21 articles)

1. **In and Beyond COVID-19: US Academic Pharmaceutical Science and Engineering Community Must Engage to Meet Critical National Needs.** *AAPS PharmSciTech* 2020; 21:153Gurvich VJ, Hussain AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449007>
2. **The Impact of COVID-19 on Plastic Surgery Residency Training.** *Aesthetic Plast. Surg.* 2020; Zingaretti N, Contessi Negrini F, Tel A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458042>
3. **Redefining undergraduate nurse teaching during the coronavirus pandemic: use of digital technologies.** *Br J Nurs* 2020; 29:566-569Leigh J, Vasilica C, Dron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463742>
4. **COVID-19 Implications on Clinical Clerkships and the Residency Application Process for Medical Students.** *Cureus* 2020; 12:e7800Akers A, Blough C, Iyer MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461867>
5. **Provision of e-learning programmes to replace undergraduate medical students' clinical general practice attachments during COVID-19 stand-down.** *Educ. Prim. Care* 2020;1-8Roskvist R, Eggleton K, Goodyear-Smith F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469632>
6. **The future of cancer research after COVID-19 pandemic: recession?** *Future Oncol* 2020; Kourie HR, Eid R, Haddad F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469283>
7. **Psychological impact of COVID-19 on ophthalmologists-in-training and practising ophthalmologists in India.** *Indian J Ophthalmol* 2020; 68:994-998Khanna RC, Honavar SG, Metla AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461412>
8. **Research Progress of Coronavirus Based on Bibliometric Analysis.** *Int J Environ Res Public Health* 2020; 17Zhai F, Zhai Y, Cong C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466477>
9. **Recommendations for Medical Student Preparedness and Equity for Dermatology Residency Applications During the COVID-19 Pandemic.** *J Am Acad Dermatol* 2020; Stewart CR, Chernoff KA, Wildman HF, Lipner SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450096>
10. **The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials.** *J Am Coll Cardiol* 2020; Bagiella E, Bhatt DL, Gaudino M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470514>
11. **Racism and the Political Economy of COVID-19: Will We Continue to Resurrect the Past?** *J. Health Polit. Policy Law* 2020; Bailey ZD, Moon JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464657>
12. **Effect of COVID-19 on Urology Residency Training: A Nationwide Survey of Program Directors by the Society of Academic Urologists.** *J Urol* 2020;101097ju0000000000001155Rosen GH, Murray KS, Greene KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463716>
13. **COVID-19: Challenges and Lessons Learned from Early Career Investigators.** *J Womens Health (Larchmt)* 2020; Denfeld Q, Erickson E, Valent A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469620>
14. **A letter to the editor: the impact of COVID-19 on intercalating and non-clinical medical students in the UK.** *Med. Educ. Online* 2020; 25:1771245Abedi M, Abedi D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449490>
15. **What COVID-19 outbreak in Iran teaches us about virtual medical education.** *Med. Educ. Online* 2020; 25:1770567Aghakhani K, Shalbfan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449487>
16. **Preparedness of medical education in China: Lessons from the COVID-19 outbreak.** *Med. Teach.* 2020;1-4Yang DY, Cheng SY, Wang SZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468890>
17. **Teaching at the paramedics school of the City of Munich during the COVID-19 pandemic.** *Notfall und Rettungsmedizin* 2020; Frieß C, Bayerl T.
18. **Increasing global awareness of timely COVID-19 healthcare guidelines through FPV training tutorials: Portable public health crises teaching method.** *Nurse Educ. Today* 2020; 91:104479Ros M, Neuwirth LS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473497>
19. **"The storm has arrived": the impact of SARS-CoV-2 on medical students.** *Perspect Med Educ* 2020; Klases JM, Vithyapathy A, Zante B, Burm S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458382>
20. **COVID-19 and Neurosurgical Education in Africa: Making lemonade from lemons.** *World Neurosurg* 2020; Kanmounye US, Esene IN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446982>
21. **Letter: Changes to neurosurgery resident education following onset of the COVID-19 pandemic.** *World Neurosurg* 2020; Pennington Z, Lubelski D, Khalafallah A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=3245031>

Elderly (8 articles)

1. **The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging).** *Ageing Res Rev* 2020;101091Fuellen G, Liesenfeld O, Kowald A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454090>
2. **Why does COVID-19 disproportionately affect older people?** *Ageing (Albany NY)* 2020; 12Mueller AL, McNamara MS, Sinclair DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470948>
3. **The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing.** *Ageing Clin. Exp. Res.* 2020; Palmer K, Monaco A, Kivipelto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458356>
4. **Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.** *Int J Infect Dis* 2020; Jang S, Rhee JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470602>
5. **Reaching older adults during the COVID-19 pandemic through social networks and Social Security Schemes in Ghana: Lessons for considerations.** *J Gerontol Soc Work* 2020;1-3Arthur-Holmes F, Agyemang-Duah W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449640>
6. **Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond.** *J. Natl. Cancer Inst.* 2020; Freedman RA, Sedrak MS, Bellon JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/>

term=32449757

7. **Recommendations for the Treatment of Elderly Patients with COVID-19 from the Taskforce for Gerontopneumology.** *Pneumologie (Stuttgart, Germany)* 2020; Stieglitz S, Frohnhofen H, Netzer N *et al.*
8. **Coronavirus: the geriatric emergency of 2020. Joint document of the Section on Geriatric Cardiology of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology.** *Rev Esp Cardiol (Engl Ed)* 2020; Bonanad C, Garcia-Blas S, Tarazona-Santabalbina FJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446793>

Epidemiology (58 articles)

1. **SARS-CoV-2 Virulence: Interplay of Floating Virus-Laden Particles, Climate, and Humans.** *Adv Biosyst* 2020:e2000105Hosseini V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449297>
2. **A novel COVID-19 based truck driver syndemic? Implications for public health, safety, and vital supply chains.** *Am. J. Ind. Med.* 2020; Lemke MK, Apostolopoulos Y, Sonmez S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452556>
3. **The effect of state-level stay-at-home orders on COVID-19 infection rates.** *Am. J. Infect. Control* 2020; Castillo RC, Staguhn ED, Weston-Farber E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461066>
4. **Ongoing Challenges Faced in the Global Control of COVID-19 Pandemic.** *Arch Med Res* 2020; Perez Perez GI, Talebi Bezmin Abadi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446538>
5. **A Statistical Modeling of the Course of COVID-19 (SARS-CoV-2) Outbreak: A Comparative Analysis.** *Asia Pac. J. Public Health* 2020:1010539520928180Ankarali H, Ankaralli S, Caskurlu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450712>
6. **Predicting intervention effect for COVID-19 in Japan: state space modeling approach.** *Biosci Trends* 2020; Kobayashi G, Sugawara S, Tamae H, Ozu T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461511>
7. **Evaluation of the potential incidence of COVID-19 and effectiveness of containment measures in Spain: a data-driven approach.** *BMC Med* 2020; 18:157Aleta A, Moreno Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456689>
8. **Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank.** *BMC Med* 2020; 18:160Niedzwiedz CL, O'Donnell CA, Jani BD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466757>
9. **Epidemiological models are important tools for guiding COVID-19 interventions.** *BMC Med* 2020; 18:152Thompson RN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448247>
10. **Asymptomatic transmission during the COVID-19 pandemic and implications for public health strategies.** *Clin Infect Dis* 2020; Huff HV, Singh A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463076>
11. **A Conceptual Discussion about R0 of SARS-CoV-2 in Healthcare Settings.** *Clin Infect Dis* 2020; Temime L, Gustin MP, Duval A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473007>
12. **Coronavirus (SARS-CoV-2) - Outbreak in North Rhine-Westphalia (District of Heinsberg) - First diagnosis of a COVID-19 manifestation in a couple.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:665-669Laufs J, Elsbernd H, Hölzl F, Winter KD.
13. **Epidemiology and control of COVID-19.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:670-674Müller O, Neuhann F, Razum O.
14. **When predictions are used to allocate scarce health care resources: three considerations for models in the era of Covid-19.** *Diagn Progn Res* 2020; 4:11Kent DM, Paulus JK, Sharp RR, Hajizadeh N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455168>
15. **Investigation and Serologic Follow-Up of Contacts of Early Confirmed Case-Patient with COVID-19, United States.** *Emerg Infect Dis* 2020; 26Chu VT, Freeman-Ponder B, Lindquist S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470316>
16. **Secondary Transmission of Coronavirus Disease from Presymptomatic Persons, China.** *Emerg Infect Dis* 2020; 26Zhang W, Cheng W, Luo L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453686>
17. **Social distancing: how religion, culture and burial ceremony undermine the effort to curb COVID-19 in South Africa.** *Emerg Microbes Infect* 2020; 9:1077-1079Jaja IF, Anyanwu MU, Iwu Jaja CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459603>
18. **COVID-19 pandemic - An African perspective.** *Emerg Microbes Infect* 2020:1-28Lone SA, Ahmad A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458760>
19. **Estimation of reproduction numbers of COVID-19 in typical countries and epidemic trends under different prevention and control scenarios.** *Front Med* 2020; Xu C, Dong Y, Yu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468343>
20. **[Health statistics and invisibility by sex and gender during the COVID-19 epidemic].** *Gac. Sanit.* 2020; Ruiz Cantero MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446594>
21. **Deaths in nine regions of Italy in February/March 2020: "Mortality Excess Loupe" for SARS-CoV-2/COVID-19-Epidemiology in Germany.** *Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany))* 2020; Morfeld P, Erren TC.
22. **Mechanistic inferences from clinical reports of SARS-CoV-2.** *Infect Dis (Lond)* 2020:1-11Jenkins MM, McCaw TR, Goepfert PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459123>
23. **The Exponential Phase of the Covid-19 Pandemic in Central Italy: An Integrated Care Pathway.** *Int J Environ Res Public Health* 2020; 17Capalbo C, Aceti A, Simmaco M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471066>
24. **Prioritizing and Analyzing the Role of Climate and Urban Parameters in the Confirmed Cases of COVID-19 Based on Artificial Intelligence Applications.** *Int J Environ Res Public Health* 2020; 17Shaffiee Haghshenas S, Pirouz B, Shaffiee Haghshenas S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466199>
25. **Italian Public Health Response to the COVID-19 Pandemic: Case Report from the Field, Insights and Challenges for the Department of Prevention.** *Int J Environ Res Public Health* 2020; 17Torri E, Sbroglio LG, Rosa ED *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456072>
26. **Evaluating Transmission Heterogeneity and Super-Spreading Event of COVID-19 in a Metropolis of China.** *Int J Environ Res Public Health* 2020; 17Zhang Y, Li Y, Wang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456346>
27. **Is Nigeria prepared and ready to respond to the COVID-19 pandemic in its conflict-affected northeastern states?** *Int J Equity Health* 2020; 19:77Tijjani SJ, Ma L.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460766>
28. **COVID-19: how to make between-country comparisons.** *Int J Infect Dis* 2020; Middelburg RA, Rosendaal FR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470605>
 29. **COVID-19 Pandemic: Marked Global Disparities in Fatalities According to Geographic Location and Universal Health Care.** *Int J MCH AIDS* 2020; 9:213-216 Dongarwar D, Salihi HM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461818>
 30. **Constructing Co-occurrence Network Embeddings to Assist Association Extraction for COVID-19 and Other Coronavirus Infectious Diseases.** *J Am Med Inform Assoc* 2020; Oniani D, Jiang G, Liu H, Shen F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458963>
 31. **Coronavirus (COVID-19): Let's Prevent Not Panic.** *J. Ayub Med. Coll. Abbottabad* 2020; 32:141-144 Mukhtar F, Mukhtar N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468775>
 32. **Early Phylogenetic Diversification of SARS-CoV-2: Determination of Variants and the Effect on Epidemiology, Immunology, and Diagnostics.** *J Clin Med* 2020; 9Kaden R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466577>
 33. **Some Lessons Learned About Diabetes and COVID-19 During the Early Stage of the Epidemic in Norway.** *J. Diabetes Sci. Technol.* 2020:1932296820929371 Birkeland KI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456527>
 34. **An introduction to economic studies, health emergencies, and COVID-19.** *J Evid Based Med* 2020; 13:161-167 Clarke L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470229>
 35. **Equitable Pandemic Preparedness and Rapid Response: Lessons from COVID-19 for Pandemic Health Equity.** *J. Health Polit. Policy Law* 2020; Alberti PM, Lantz PM, Wilkins CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464654>
 36. **Understanding the Anemic Global Response to COVID-19.** *J. Health Polit. Policy Law* 2020; Busby JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464668>
 37. **Inferring super-spreading from transmission clusters of COVID-19 in Hong Kong, Japan and Singapore.** *J Hosp Infect* 2020; On Kwok K, Hin Chan HH, Huang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446721>
 38. **Co-infections in people with COVID-19: a systematic review and meta-analysis.** *J Infect* 2020; Lansbury L, Lim B, Baskaran V, Lim WS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473235>
 39. **Imported and locally transmitted mild SARS-CoV-2 pneumonia cases in Japan.** *J Infect Chemother* 2020; Tochitani K, Iwamoto N, Motobayashi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471794>
 40. **Response to Malkovsky.** *J Infect Dis* 2020; Zeng QL, Ji F, Zhang JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473012>
 41. **Racial Disparities in COVID-19 Deaths Reveal Harsh Truths About Structural Inequality in America.** *J Intern Med* 2020; Anyane-Yeboah A, Sato T, Sakuraba A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452046>
 42. **Using Reports of Symptoms and Diagnoses on Social Media to Predict COVID-19 Case Counts in Mainland China: Observational Infection Study.** *J Med Internet Res* 2020; 22:e19421 Shen C, Chen A, Luo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452804>
 43. **Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: Meta-analysis and sensitivity analysis.** *J Med Virol* 2020; He W, Yi GY, Zhu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470164>
 44. **The COVID-19 infection: lessons from the Italian experience.** *J. Public Health Policy* 2020; Romagnani P, Gnone G, Guzzi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472024>
 45. **Projecting the impact of COVID-19 pandemic on childhood obesity in the U.S.: A microsimulation model.** *J Sport Health Sci* 2020; An R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454174>
 46. **Familial cluster of SARS-CoV-2 infection associated with a railway journey.** *J Travel Med* 2020; Qiu S, Liu H, Li P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463446>
 47. **Pandemic COVID-19 Joins History's Pandemic Legion.** *mBio* 2020; 11Morens DM, Daszak P, Markel H, Taubenberger JK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471830>
 48. **Together against COVID-19.** *MMW-Fortschritte der Medizin* 2020; 162:73Red.
 49. **Caution is needed on the effect of altitude on the pathogenesis of SAR-CoV-2 virus.** *Respir. Physiol. Neurobiol.* 2020:103464 Burtcher J, Burtcher M, Millet GP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447057>
 50. **First detection of SARS-CoV-2 in untreated wastewaters in Italy.** *Sci Total Environ* 2020; 736:139652 La Rosa G, Iaconelli M, Mancini P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464333>
 51. **Asymmetric nexus between temperature and COVID-19 in the top ten affected provinces of China: A current application of quantile-on-quantile approach.** *Sci Total Environ* 2020; 736:139115 Shahzad F, Shahzad U, Fareed Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470687>
 52. **The COVID-19 Pandemic in Japan.** *Surg Today* 2020; Watanabe M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462468>
 53. **COVID-19 Waves: Importance of Accumulative Mortality per Million Inhabitants.** *Tohoku J. Exp. Med.* 2020; 251:47-49 Delgado CA, Shimabuku RL, Chiroque-Solano PM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461502>
 54. **Estimation of the Serial Interval and Basic Reproduction Number of COVID-19 in Qom, Iran, and Three Other Countries: A Data-Driven Analysis in the Early Phase of the Outbreak.** *Transbound Emerg Dis* 2020; Aghaali M, Kolifarhood G, Nikbakht R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473049>
 55. **Estimating the serial interval of the novel coronavirus disease (COVID-19) based on the public surveillance data in Shenzhen, China from January 19 to February 22, 2020.** *Transbound Emerg Dis* 2020; Wang K, Zhao S, Liao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452648>
 56. **What We Need to Consider During and After the SARS-CoV-2 Pandemic.** *Vector Borne Zoonotic Dis.* 2020; Valdivia-Granda WA, Richt JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469633>
 57. **[Epidemiological characteristics of infection in COVID-19 close contacts in Ningbo city].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:667-671 Chen Y, Wang AH, Yi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447904>
 58. **[Risk assessment of global COVID-19 imported cases into China].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:E070 Shen SP, Wei YY, Zhao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455514>

Gastro-enterology-hepatology (15 articles)

1. **Plans to Reactivate Gastroenterology Practices Following the COVID-19 Pandemic: A Survey of North American Centers.** *Clin Gastroenterol Hepatol* 2020; Kushnir VM, Berzin TM, Elmunzer BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447019>
2. **Successful Conservative Management of Acute Appendicitis in a Coronavirus Disease 2019 (COVID-19) Patient.** *Cureus* 2020; 12:e7834Suwanwongse K, Shabarek N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32467809>
3. **Clinical Insights into the Gastrointestinal Manifestations of COVID-19.** *Dig. Dis. Sci.* 2020; Kopel J, Perisetti A, Gajendran M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447742>
4. **Clinical Questions and Answers on Gastrointestinal Endoscopy during the Novel COVID-19 Pandemic.** *Dig Endosc* 2020; Furuta T, Irisawa A, Matsumoto T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470171>
5. **Control measures to prevent Coronavirus disease 2019 COVID-19 pandemic in endoscopy centers: a multi-centre study.** *Dig Endosc* 2020; Huang Q, Liu G, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473036>
6. **Initial Gastrointestinal Manifestations in Patients with SARS-CoV-2 in 112 patients from Veracruz (Southeastern Mexico).** *Gastroenterology* 2020; Remes-Troche JM, Ramos-de-la-Medina A, Manriquez-Reyes M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446696>
7. **Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations.** *Hepatol Int* 2020; Lau G, Sharma M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447721>
8. **IBD in the Times of COVID-19.** *Inflamm. Bowel Dis.* 2020; Hernandez Benabe S, Langshaw AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448895>
9. **An international multicentre study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise.** *J Hepatol* 2020; Chew CA, Iyer SG, Chieh Kow AW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454041>
10. **SARS-CoV-2 related liver impairment - perception may not be the reality.** *J Hepatol* 2020; Philips CA, Ahamed R, Augustine P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454042>
11. **Features of Enteric Disease from Human Coronaviruses: Implications for COVID-19.** *J Med Virol* 2020; Cimolai N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462689>
12. **Recommendations for Performing Bronchoscopy in Times of the COVID-19 Pandemic.** *Pneumologie* 2020; 74:260-262Darwiche K, Ross B, Gesierich W *et al.*
13. **Knowledge of Latin American gastroenterologists and endoscopists regarding SARS-CoV-2 infection.** *Rev. Gastroenterol. Mex.* 2020; Ruiz-Manriquez J, Leon-Lara X, Campos-Murguia A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466830>
14. **The risk of COVID-19 transmission by laparoscopic smoke may be lower than for laparotomy: a narrative review.** *Surg. Endosc.* 2020; Mintz Y, Arezzo A, Boni L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458289>
15. **Liver injury in COVID-19: The current evidence.** *United European Gastroenterol J* 2020; 8:509-519Alqahtani SA, Schattenberg JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450787>

Guidelines -Consensus (23 articles)

1. **Emergency Radiology During the COVID-19 Pandemic: The Canadian Association of Radiologists Recommendations for Practice.** *Can Assoc Radiol J* 2020;846537120930344Redmond CE, Nicolaou S, Berger FH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468845>
2. **Practical Guidance for Outpatient Spasticity Management during the Coronavirus (COVID-19) Pandemic: Canadian Spasticity COVID-19 Task Force.** *Can. J. Neurol. Sci.* 2020;1-17Reebye R, Finlayson H, May C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450934>
3. **Recommendations for the use of vascular access in the COVID-19 patients: an Italian perspective.** *Crit Care* 2020; 24:269Pittiruti M, Pinelli F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466803>
4. **COVID-19 guidelines for the prioritization of operations for malignant thoracic diseases.** *Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizin* 2020; Hekmat K, Bruns CJ.
5. **Rapid guide to the management of cardiac patients during the COVID-19 pandemic in Egypt: "a position statement of the Egyptian Society of Cardiology".** *Egypt Heart J* 2020; 72:30Shaheen S, Awwad O, Shokry K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462497>
6. **Evaluation of World Health Organization-Recommended Hand Hygiene Formulations.** *Emerg Infect Dis* 2020; 26Suchomel M, Eggers M, Maier S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459621>
7. **ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer.** *ESMO Open* 2020; 5Vecchione L, Stintzing S, Pentheroudakis G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457036>
8. **Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.** *Eur J Heart Fail* 2020; Zhang Y, Stewart Coats AJ, Zheng Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463543>
9. **Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia during the COVID-19 Pandemic: A Living Document.** *Heart Lung Circ.* 2020; Kumar S, Haqqani H, Wynn G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451232>
10. **CSANZ Imaging Council Position Statement on Echocardiography Services During the COVID-19 Pandemic.** *Heart Lung Circ.* 2020; Wahi S, Thomas L, Stanton T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32467031>
11. **Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations.** *Hepatol Int* 2020; Lau G, Sharma M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447721>
12. **Evolving consensus on managing vitreo-retina and uvea practice in post-COVID-19 pandemic era.** *Indian J Ophthalmol* 2020; 68:962-973Gupta V, Rajendran A, Narayanan R *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461407>
13. **Cardiac imaging procedures and the COVID-19 pandemic: recommendations of the European Society of Cardiovascular Radiology (ESCR).** *Int. J. Cardiovasc. Imaging* 2020; Beitzke D, Salgado R, Francone M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451877>
 14. **International Guidelines And Recommendations For Surgery During Covid-19 Pandemic: A Systematic Review.** *Int J Surg* 2020; Moletta L, Pierobon ES, Capovilla G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454253>
 15. **SARS-CoV-2 infection, male fertility and sperm cryopreservation: a position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) (Societa Italiana di Andrologia e Medicina della Sessualita).** *J. Endocrinol. Invest.* 2020; Corona G, Baldi E, Isidori AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462316>
 16. **Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experience.** *J Infect Public Health* 2020; Algaissi AA, Alharbi NK, Hassanain M, Hashem AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451260>
 17. **The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries.** *J Neurol Sci* 2020; 414:116884 Roman GC, Spencer PS, Reis J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464367>
 18. **Consensus document of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC), the Spanish Society of Otorhinolaryngology and Head and Neck Surgery (SEORL-CCC) and the Spanish Society of Anesthesiology and Resuscitation (SEDAR) on tracheotomy in patients with COVID-19 infection.** *Med. Intensiva* 2020; Martin Delgado MC, Aviles-Jurado FX, Alvarez Escudero J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466990>
 19. **Guidance for Resumption of Routine Electrodiagnostic Testing during the COVID-19 Pandemic.** *Muscle Nerve* 2020; Desai U, Kassardjian CD, Del Toro D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462675>
 20. **Virtual Dysphagia Evaluation: Practical Guidelines for Dysphagia Management in the Context of the COVID-19 Pandemic.** *Otolaryngol Head Neck Surg* 2020:194599820931791 Soldatova L, Williams C, Postma GN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450732>
 21. **Recommendations for the Treatment of Elderly Patients with COVID-19 from the Taskforce for Gerontopneumology.** *Pneumologie (Stuttgart, Germany)* 2020; Stieglitz S, Frohnhofen H, Netzer N *et al.*
 22. **Decision support tool and suggestions for the development of guidelines for the helicopter transport of patients with COVID-19.** *Scand. J. Trauma Resusc. Emerg. Med.* 2020; 28:43 Bredmose PP, Diczbalis M, Butterfield E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450877>
 23. **Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.** *Vox Sang* 2020; Epstein J, Smid M, Wendel S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464700>

Imaging (12 articles)

1. **A Comparison of Clinical and Chest CT Findings in Patients With Influenza A (H1N1) Virus Infection and Coronavirus Disease (COVID-19).** *AJR Am J Roentgenol* 2020:1-7 Yin Z, Kang Z, Yang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452731>
2. **Application of CareDose 4D combined with Karl 3D technology in the low dose computed tomography for the follow-up of COVID-19.** *BMC Med. Imaging* 2020; 20:56 Li J, Wang X, Huang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448136>
3. **COVID-19: Safe Guidelines for Breast Imaging During the Pandemic.** *Can Assoc Radiol J* 2020:846537120928864 Seely JM, Scaranelo AM, Yong-Hing C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452700>
4. **Imaging evaluation of COVID-19 in the emergency department.** *Emerg Radiol* 2020; Pakray A, Walker D, Figacz A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449099>
5. **Lung ultrasonography in COVID-19: a gamechanger in the Stroke Unit?** *Eur. J. Neurol.* 2020; Lugnan C, Tommasini V, Furlanis G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449272>
6. **Any unique image biomarkers associated with COVID-19?** *Eur Radiol* 2020; Pu J, Leader J, Bandos A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462445>
7. **Nasopharyngeal swab or clinical-radiological evidence: the dark side of the moon for cancer patients in the COVID-19 era.** *Future Oncol* 2020; Veccia A, Kinspergher S, Dipasquale M, Caffo O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452225>
8. **CSANZ Imaging Council Position Statement on Echocardiography Services During the COVID-19 Pandemic.** *Heart Lung Circ.* 2020; Wahi S, Thomas L, Stanton T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32467031>
9. **Progression of CXR features on a COVID-19 survivor.** *IDCases* 2020; 21:e00834 Abdelnour LH, Abdalla ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461911>
10. **Cardiac imaging procedures and the COVID-19 pandemic: recommendations of the European Society of Cardiovascular Radiology (ESCR).** *Int. J. Cardiovasc. Imaging* 2020; Beitzke D, Salgado R, Francone M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451877>
11. **COVID-19 - More Lung Pocus and Sparing Use of Stethoscope, Chest X-Ray and Lung CT.** *Praxis* 2020:1-9 Osterwalder J.
12. **Lung Ultrasound in Patients with Acute Respiratory Failure Reduces Conventional Imaging and Health Care Provider Exposure to COVID-19.** *Ultrasound Med. Biol.* 2020; Mongodi S, Orlando A, Arisi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451194>

Immune response (11 articles)

1. **Immunity-Boosting Spices and the Novel Coronavirus.** *ACS Chem Neurosci* 2020; Elsayed Y, Khan NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452670>

2. **Correlation between immune response and self-reported depression during convalescence from COVID-19.** *Brain Behav Immun* 2020; Yuan B, Li W, Liu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464158>
3. **The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?** *Cell Host Microbe* 2020; McKechnie JL, Blish CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464098>
4. **COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.** *Clin Rheumatol* 2020; Ouedraogo DD, Tiendrebeogo WJS, Kabore F, Ntsiba H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472461>
5. **Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.** *Diabetes Metab Syndr* 2020; 14:713-714 Erol A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470851>
6. **Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China.** *Immunology* 2020; Tan M, Liu Y, Zhou R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460357>
7. **The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?** *Inflamm Res* 2020; Bellinvia S, Edwards CJ, Schisano M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468151>
8. **Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.** *J Med Virol* 2020; Ni M, Tian FB, Xiang DD, Yu B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470153>
9. **Novel Immunoglobulin Domain Proteins Provide Insights into Evolution and Pathogenesis of SARS-CoV-2-Related Viruses.** *mBio* 2020; 11 Tan Y, Schneider T, Leong M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471829>
10. **Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.** *Med Hypotheses* 2020; 143:109871 Allahverdi Khani M, SalehiRad M, Darbeheshti S, Motaghinejad M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470789>
11. **Cytokine storm in COVID-19 and parthenolide: preclinical evidence.** *Phytother. Res.* 2020; Bahrami M, Kamalinejad M, Latifi SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472655>

Management – misc. diseases (88 articles)

1. **Delayed Diagnosis of Pediatric Appendicitis during the COVID-19 Pandemic.** *Acta Paediatr* 2020; Snapiri O, Rosenberg Danziger C, Krause I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460364>
2. **The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing.** *Ageing Clin. Exp. Res.* 2020; Palmer K, Monaco A, Kivipelto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458356>
3. **Critical medication shortages further dwindling hospital resources during COVID-19.** *Am J Emerg Med* 2020; Farrell NM, Hayes BD, Linden JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471781>
4. **Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes.** *Ann. Clin. Microbiol. Antimicrob.* 2020; 19:21 Togun T, Kampmann B, Stoker NG, Lipman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446305>
5. **Out of Hospital Management of LVAD Patients During COVID-19 Outbreak.** *Artif. Organs* 2020; Mariana S, Schmitto JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464685>
6. **Can you draw the picture of happiness- Treatment of a young woman with breast cancer during the COVID-19 pandemic.** *Asian J Psychiatr* 2020; 52:102174 Cetin B, Rakici S, Gumusay O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464519>
7. **Hemato- Oncology Care in COVID-19 Pandemic: Crisis within a Crisis.** *Asian Pac J Cancer Prev* 2020; 21:1173-1175 Seth T, Shankar A, Roy S, Saini D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458618>
8. **Our First Month of Delivering the Prostate Cancer Diagnostic Pathway within the Limitations of COVID-19 Using Local Anaesthetic Transperineal Biopsy.** *BJU Int* 2020; Popert R, Kum F, MacAskill F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455471>
9. **Emergency Radiology During the COVID-19 Pandemic: The Canadian Association of Radiologists Recommendations for Practice.** *Can Assoc Radiol J* 2020:846537120930344 Redmond CE, Nicolaou S, Berger FH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468845>
10. **Practical Guidance for Outpatient Spasticity Management during the Coronavirus (COVID-19) Pandemic: Canadian Spasticity COVID-19 Task Force.** *Can. J. Neurol. Sci.* 2020:1-17 Reebye R, Finlayson H, May C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450934>
11. **Preparing for the coming transnational cancer crisis amid the COVID-19 pandemic.** *Cancer Causes Control* 2020; Ip EC, Lee SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472231>
12. **The impact of the COVID-19 pandemic on renal transplantation in the UK.** *Clin Med (Lond)* 2020; Sharma V, Shaw A, Lowe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457133>
13. **COVID-19 and Asthma: Reflection During the Pandemic.** *Clin. Rev. Allergy Immunol.* 2020; Liu S, Zhi Y, Ying S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468411>
14. **Taking care of systemic sclerosis patients during COVID-19 pandemic: rethink the clinical activity.** *Clin Rheumatol* 2020; Minniti A, Maglione W, Pignataro F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462423>
15. **Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid.** *Clin. Transl. Oncol.* 2020; Rogado J, Obispo B, Pangua C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449128>
16. **Successful Conservative Management of Acute Appendicitis in a Coronavirus Disease 2019 (COVID-19) Patient.** *Cureus* 2020; 12:e7834 Suwanwongse K, Shabarek N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32467809>
17. **The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population.** *Curr. Oncol. Rep.* 2020; 22:60 Asokan I, Rabadia SV, Yang EH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462289>
18. **Novel Coronavirus (COVID-19) and Dentistry-A Comprehensive Review of Literature.** *Dent J (Basel)* 2020; 8 Barabari P, Moharamzadeh K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455612>
19. **COVID-19 guidelines for the prioritization of operations for malignant thoracic diseases.** *Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizin* 2020; Hekmat K, Bruns CJ.
20. **How badly is the coronavirus pandemic affecting orthopaedic and trauma surgery clinics? : An analysis of the first 5 weeks.** *Der Orthopäde* 2020; von Dercks N, Körner C, Heyde CE, Theopold J.

21. **Patients with bullous disorders during COVID-19 period: management and adherence to treatment.** *Dermatol Ther* 2020:e13697De Fata Salvatore G, Villani A, Fabbrocini G, Di Guida A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458422>
22. **Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.** *Dermatol Ther* 2020:e13686Karadag AS, Aslan Kayiran M, Lotti T, Wollina U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458530>
23. **Is climate change the next pandemic for dermatology? Lessons from COVID-19.** *Dermatol Ther* 2020; Patruno C, Nistico SP, Fabbrocini G, Napolitano M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447805>
24. **Considerations for Safety in the Use of Systemic Medications for Psoriasis and Atopic Dermatitis during the COVID-19 pandemic.** *Dermatol Ther* 2020; Ricardo JW, Lipner SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458536>
25. **Restructuring an Academic Dermatology Practice During the COVID-19 Pandemic.** *Dermatol Ther* 2020; Sheriff T, Murrell OG, Murrell DF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458551>
26. **Waiting for the surge: COVID-19 patients in the intensive care unit - An overview.** *Deutsche Apotheker Zeitung* 2020; 60Stahl V.
27. **ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer.** *ESMO Open* 2020; 5Vecchione L, Stintzing S, Pentheroudakis G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457036>
28. **Impact of the COVID-19 pandemic in nuclear medicine departments: preliminary report of the first international survey.** *Eur J Nucl Med Mol Imaging* 2020; Annunziata S, Bauckneht M, Albano D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462398>
29. **Ophthalmology and SARS-CoV-2: Blind toward those who fight blindness?** *Eur. J. Ophthalmol.* 2020;1120672120929961Arrigo A, Aragona E, Parodi MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450718>
30. **Hematopoietic stem cell transplantation dilemma during the COVID-19 era.** *Future Oncol* 2020; Samaha R, Kattan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458703>
31. **Evolving consensus on managing vitreo-retina and uvea practice in post-COVID-19 pandemic era.** *Indian J Ophthalmol* 2020; 68:962-973Gupta V, Rajendran A, Narayanan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461407>
32. **The role of a Coronavirus disease 2019 pharmacist: an Australian perspective.** *Int J Clin Pharm* 2020; Nguy J, Hitchen SA, Hort AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472325>
33. **From high volume to "zero" proctology: Italian experience in the COVID era.** *Int. J. Colorectal Dis.* 2020; Mascagni D, Eberspacher C, Mascagni P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468103>
34. **Covid-19 Pandemic: What Changes for Dentists and Oral Medicine Experts? A Narrative Review and Novel Approaches to Infection Containment.** *Int J Environ Res Public Health* 2020; 17Bizzoca ME, Campisi G, Muzio LL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471083>
35. **COVID-19 Disease in Children: What Dentists Should Know and Do to Prevent Viral Spread. The Italian Point of View.** *Int J Environ Res Public Health* 2020; 17Ferrazzano GF, Ingenito A, Cantile T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455859>
36. **The Precautions Required for the Safe Return of Elective Surgery - A Letter to the Editor in Response to "Impact of the coronavirus (COVID-19) pandemic on surgical practice - Part 2 (surgical prioritisation)".** *Int J Surg* 2020; Cheng SO, Liu A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450264>
37. **International Guidelines And Recommendations For Surgery During Covid-19 Pandemic: A Systematic Review.** *Int J Surg* 2020; Moletta L, Pierobon ES, Capovilla G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454253>
38. **Staying home during "COVID-19" decreased fractures, but trauma did not quarantine in one hundred and twelve adults and twenty eight children and the "tsunami of recommendations" could not lockdown twelve elective operations.** *Int. Orthop.* 2020; Hernigou J, Morel X, Callewier A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451655>
39. **A clinical pathway for pre-operative screening of COVID-19 and its influence on clinical outcome in patients with traumatic fractures.** *Int. Orthop.* 2020; Meng Y, Leng K, Shan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468202>
40. **Impact of the COVID-19 pandemic on patients suffering from musculoskeletal tumours.** *Int. Orthop.* 2020; Thaler M, Khosravi I, Leithner A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451657>
41. **Challenges and response in the medical management of the orthopaedic department during the coronavirus disease 2019 pandemic: strategies in Wuhan, China.** *Int. Orthop.* 2020; Wu W, Xiong W, Kang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468201>
42. **Changes of clinical activities in an orthopaedic institute in North Italy during the spread of COVID-19 pandemic: a seven-week observational analysis.** *Int. Orthop.* 2020; Zagra L, Faraldi M, Pregliasco F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449043>
43. **Survival strategy of urology department during the COVID-19 era.** *Int. Urol. Nephrol.* 2020; Choi SY, Kim TH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472250>
44. **The impact of COVID-19 on urologic practice, medical education, and training.** *Int. Urol. Nephrol.* 2020; Diokno AC, Devries JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468167>
45. **A Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services.** *J Allergy Clin Immunol Pract* 2020; Searing DA, Dutmer CM, Fleischer DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450236>
46. **Rescheduling Nonurgent Care in Radiology: Implementation During the Coronavirus Disease 2019 (COVID-19) Pandemic.** *J Am Coll Radiol* 2020; Vagal A, Mahoney M, Allen B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473108>
47. **Preparedness and disinfection of anesthetic equipment in COVID-19.** *J. Clin. Anesth.* 2020; 66:109924Duan N, Gao W, Wang Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473502>
48. **Preoperative assessment organization in the time of the outbreak COVID-19.** *J. Clin. Anesth.* 2020; 65:109882Elkoundi A, Jaafari A, Ababou M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447166>
49. **Managing Bladder Cancer Care during the COVID-19 Pandemic Using a Team-Based Approach.** *J Clin Med* 2020; 9Wang T, Liu S, Joseph T, Lyou Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455894>
50. **Aesthetic dermatology procedures in coronavirus-days.** *J Cosmet Dermatol* 2020; Tursen U, Tursen B, Lotti T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460391>

51. **Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.** *J. Cutan. Med. Surg.* 2020;1203475420929250 Nassim D, Jfri A, Litvinov IV, Netchiporouk E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449619>
52. **Use of systemic therapies for psoriasis in the COVID-19 era.** *J Dermatolog Treat* 2020;1-14 Kearns DG, Uppal S, Chat VS, Wu JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459567>
53. **The COVID-19 outbreak in dermatologic surgery: resetting clinical priorities.** *J Eur Acad Dermatol Venereol* 2020; Rossi E, Trakatelli M, Giacomelli L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455485>
54. **The role of the orthopaedic surgeon in the COVID-19 era: cautions and perspectives.** *J Exp Orthop* 2020; 7:35 Ambrosio L, Vadala G, Russo F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458150>
55. **COVID-19 risk contagion: Organization and procedures in a South Italy geriatric oncology ward.** *J. Geriatr. Oncol.* 2020; Gambardella C, Pagliuca R, Pomilla G, Gambardella A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32467027>
56. **An international multicentre study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise.** *J Hepatol* 2020; Chew CA, Iyer SG, Chieh Kow AW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454041>
57. **Coronavirus Disease (COVID-19) Outbreak and Its Impact on Spinal Daily Practice : Preliminary Report from a Single (Regional) University Hospital in Republic of Korea.** *J. Korean Neurosurg. Soc.* 2020; Ham CH, Moon HJ, Kim JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455517>
58. **The Landscape of Prescription Drug Shortages During the COVID-19 Pandemic.** *J. Med. Toxicol.* 2020; Fox ER, Stolbach AI, Mazer-Amirshahi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458230>
59. **Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond.** *J. Natl. Cancer Inst.* 2020; Freedman RA, Sedrak MS, Bellon JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449757>
60. **Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.** *J Pharm Policy Pract* 2020; 13:18 Elbeddini A, Yeats A, Lee S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454982>
61. **Economic implications of the COVID-19 pandemic on the plastic surgery community.** *J. Plast. Reconstr. Aesthet. Surg.* 2020; Inglesby DC, Boyd CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471766>
62. **Reply to Re: COVID-19 and the Urology Match: Perspectives and a Call to Action.** *J Urol* 2020;101097ju0000000000001146 Gabrielson AT, Kohn TP, Clifton MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459557>
63. **Re: COVID-19 and the Urology Match: Perspectives and a Call To Action.** *J Urol* 2020;101097ju0000000000001145 Warren CJ, Davis M, Sadeghi-Nejad H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459548>
64. **Endocrine surgery during and after the COVID-19 epidemic: Expert guidelines from AFCE.** *J Visc Surg* 2020; Baud G, Brunaud L, Lifante JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448761>
65. **How and why are rheumatologists relevant to COVID-19?** *Joint Bone Spine* 2020; Felten R, Chatelus E, Arnaud L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451147>
66. **Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020.** *Joint Bone Spine* 2020; Richez C, Flipo RM, Berenbaum F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473418>
67. **Cancer treatment during COVID-19 pandemic.** *Med. Oncol.* 2020; 37:58 Jindal V, Sahu KK, Gaikazian S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472216>
68. **Care of ophthalmological patients during the COVID-19 pandemic: A rapid scoping review.** *Medwave* 2020; 20:e7902 Vargas-Peirano M, Navarrete P, Diaz T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469854>
69. **Guidance for Resumption of Routine Electrodiagnostic Testing during the COVID-19 Pandemic.** *Muscle Nerve* 2020; Desai U, Kassardjian CD, Del Toro D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462675>
70. **A Structured Approach for Safely Reintroducing Bariatric Surgery in a COVID-19 Environment.** *Obes. Surg.* 2020; Daigle CR, Augustin T, Wilson R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458364>
71. **The Impact of the Pandemic on Otolaryngology Patients With Negative COVID-19 Status: Commentary and Insights From Orbital Emergencies.** *Otolaryngol Head Neck Surg* 2020;194599820931082 Fastenberg JH, Bottalico D, Kennedy WA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450752>
72. **Safety and Prognosis in Percutaneous vs Surgical Tracheostomy in 27 Patients With COVID-19.** *Otolaryngol Head Neck Surg* 2020;194599820931801 Riestra-Ayora J, Yanes-Diaz J, Penuelas O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450761>
73. **Endoscopic Skull Base Surgery Protocol From the Frontlines: Transnasal Surgery During the COVID-19 Pandemic.** *Otolaryngol Head Neck Surg* 2020;194599820931836 Spock T, Kessler R, Lerner D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452722>
74. **Implementation of Preoperative Screening Protocols in Otolaryngology During the COVID-19 Pandemic.** *Otolaryngol Head Neck Surg* 2020;194599820931041 Urban MJ, Patel TR, Raad R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452746>
75. **Evolving Management of COVID-19: A Multi-institutional Otolaryngology Perspective.** *Otolaryngol Head Neck Surg* 2020;194599820930244 Wickemeyer JL, Billings KR, Valika TS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450770>
76. **CONTROLS TO MINIMIZE DISRUPTION OF THE PHARMACEUTICAL SUPPLY CHAIN DURING THE COVID-19 PANDEMIC.** *PDA J. Pharm. Sci. Technol.* 2020; Cundell AM, Guilfoyle DE, Kreil TR, Sawant A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32467176>
77. **Global drug shortages due to COVID-19: Impact on patient care and mitigation strategies.** *Res Social Adm Pharm* 2020; Badreldin HA, Atallah B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446652>
78. **Modifications of emergency dental clinic protocols to combat COVID-19 transmission.** *Spec. Care Dentist* 2020; Long RH, Ward TD, Pruett ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447777>
79. **Clinical recommendations on lung cancer management during the COVID-19 pandemic.** *Thorac Cancer* 2020; Xu Y, Liu H, Hu K, Wang M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469164>

80. **The COVID-19 Pandemic from an Ophthalmologist's Perspective.** *Trends Mol. Med.* 2020; 26:529-531 Bacherini D, Biagini I, Lenzetti C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470381>
81. **Challenges in Tuberculosis Clinical Trials in the Face of the COVID-19 Pandemic: A Sponsor's Perspective.** *Trop Med Infect Dis* 2020; 5Rusen ID. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471274>
82. **Elective lung cancer surgery in the COVID-19 era: how do we do it?** *Tumori* 2020;300891620931568 Bilkhu R, Bille A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462984>
83. **Perspectives from Italy during the COVID-19 pandemic: nationwide survey-based focus on minimally invasive HPB surgery.** *Updates Surg.* 2020; Aldrighetti L, Boggi U, Falconi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472403>
84. **Emergency general surgery in Italy during the COVID-19 outbreak: first survey from the real life.** *World J Emerg Surg* 2020; 15:36 Patrìti A, Baiocchi GL, Catena F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448333>
85. **The impact of COVID-19 pandemic on urological emergencies: a single-center experience.** *World J Urol.* 2020; Motterle G, Morlacco A, Iafrate M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447443>
86. **An Australian Response to the COVID-19 Pandemic and its Implications on the Practice of Neurosurgery.** *World Neurosurg* 2020; Antony J, James WT, Neriamparambil AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450310>
87. **Impact of COVID-19 on an Academic Neurosurgery Department: The Johns Hopkins Experience.** *World Neurosurg* 2020; Khalafallah AM, Jimenez AE, Lee RP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461176>
88. **Impact of the COVID-19 Pandemic on Neurosurgical Practice at an Academic Tertiary Referral Center: A Comparative Study.** *World Neurosurg* 2020; Noureldine MHA, Pressman E, Krafft PR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450314>

Management (35 articles)

1. **[COVID-19 and The Invisible Damage: The Role of The Family Physician].** *Acta Med Port* 2020; Gouveia M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459169>
2. **Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis.** *Am. J. Epidemiol.* 2020; Risch HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458969>
3. **Airway management team for patients with COVID-19: A new role for emergency medicine pharmacists.** *Am. J. Health Syst. Pharm.* 2020; Faine BA, Carroll E, Decléene J, Zepeski A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462173>
4. **Absence of nosocomial transmission of coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in the pre-pandemic phase in Hong Kong.** *Am. J. Infect. Control* 2020; Cheng VCC, Wong SC, Chuang VWM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461068>
5. **Comparison of three tracheal intubation methods for reducing droplet spread for use in COVID-19 patients.** *Br J Anaesth* 2020; Yang SS, Zhang M, Chong JJR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448441>
6. **Therapeutic alternatives and strategies for drug conservation in the intensive care unit during times of drug shortage: a report of the Ontario COVID-19 ICU Drug Task Force.** *Can J Anaesth* 2020; Kanji S, Burry L, Williamson D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458267>
7. **Clinical Outcomes of COVID-19 with Evidence-Based Supportive Care.** *Clin Infect Dis* 2020; Larson DT, Sherner JH, Gallagher KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472675>
8. **Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.** *Clin Rheumatol* 2020; Dai J, Xiong Y, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451729>
9. **Treatment algorithm for COVID-19: a multidisciplinary point of view.** *Clin Rheumatol* 2020; Galluccio F, Ergonenc T, Garcia Martos A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472459>
10. **Effect of flow and cannula size on generated pressure during nasal high flow.** *Crit Care* 2020; 24:248 Pinkham M, Tatkov S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448344>
11. **Early awake prone position combined with high-flow nasal oxygen therapy in severe COVID-19: a case series.** *Crit Care* 2020; 24:250 Xu Q, Wang T, Qin X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448330>
12. **Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.** *Crit. Rev. Oncol. Hematol.* 2020; 151:102982 Jafari A, Dadkhahfar S, Perseh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460133>
13. **Do not discontinue ACE inhibitors and sartans!: RAS inhibitors could even protect hypertensive patients against severe COVID-19 progressions.** *Deutsche Apotheker Zeitung* 2020; 60.
14. **COVID-19 Triage: Who is an inpatient? The Essen triage model.** *Deutsche medizinische Wochenschrift (1946)* 2020; Fistera D, Risse J, Manegold R *et al.*
15. **Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:682-686 Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F.
16. **COVID-19-Response - Strategies of the Task-Force Coronavirus and experiences upon implementation in the management of 115 cases at the University Medical Center Freiburg.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:657-664 Rieg S, Busch HJ, Hans F *et al.*
17. **Postintubation Dysphagia During COVID-19 Outbreak-Contemporary Review.** *Dysphagia* 2020; Frajkova Z, Tedla M, Tedlova E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468193>
18. **Indications and timing for tracheostomy in patients with SARS CoV2-related.** *Eur Arch Otorhinolaryngol* 2020; Ferri E, Boscolo Nata F, Pedruzzi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458121>
19. **Analysis of SARS-CoV-2 Screening Clinic (Including Drive-Through System) Data at a Single University Hospital in South Korea from 27 January 2020 to 31 March 2020 during the COVID-19 Outbreak.** *Healthcare (Base)* 2020; 8Chang MC, Seo WS, Park D, Hur J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466523>
20. **Evaluation of fluid responsiveness during COVID-19 pandemic: what are the remaining choices?** *J. Anesth.* 2020; Hasanin A, Mostafa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451626>

21. **Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.** *J. Cardiovasc. Transl. Res.* 2020; Fudim M, Qadri YJ, Ghadimi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458400>
22. **Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.** *J Med Virol* 2020; Ma SQ, Zhang J, Wang YS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470160>
23. **Palliative Care Utilization among Patients with COVID-19 in an Underserved Population: A Single-Center Retrospective Study.** *J Pain Symptom Manage* 2020; Haydar A, Lo KB, Goyal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454186>
24. **Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.** *J. Thromb. Thrombolysis* 2020; Artifoni M, Danic G, Gautier G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451823>
25. **Nutrition Therapy in Critically Ill Patients with Coronavirus Disease (COVID-19).** *JPEN J. Parenter. Enteral Nutr.* 2020; Martindale R, Patel JJ, Taylor B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462719>
26. **Selecting coronavirus disease 2019 patients with negligible risk of progression: early experience from non-hospital isolation facility in Korea.** *Korean J. Intern. Med.* 2020; Choe PG, Kang EK, Lee SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460457>
27. **Management of Upper Airway Bleeding in COVID-19 Patients on Extracorporeal Membrane Oxygenation.** *Laryngoscope* 2020; LoSavio PS, Patel T, Urban MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470179>
28. **Virtual Dysphagia Evaluation: Practical Guidelines for Dysphagia Management in the Context of the COVID-19 Pandemic.** *Otolaryngol Head Neck Surg* 2020;194599820931791Soldatova L, Williams C, Postma GN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450732>
29. **Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.** *Pharmacol. Res.* 2020;104950Viecca M, Radovanovic D, Forleo GB, Santus P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450344>
30. **Food as medicine: a possible preventive measure against coronavirus disease (COVID-19).** *Phytother. Res.* 2020; Fan Y, Zhang Y, Tariq A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468635>
31. **Prevention is life- and cost-saving.** *Prev. Med.* 2020;106150Baussano I, Sankaranarayanan R, Weiderpass E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473263>
32. **Prone positioning to improve oxygenation and relieve respiratory symptoms in awake, spontaneously breathing non-intubated patients with COVID-19 pneumonia.** *Respir Med Case Rep* 2020; 30:101096Sztajnbok J, Maselli-Schoueri JH, Cunha de Resende Brasil LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455107>
33. **Decision support tool and suggestions for the development of guidelines for the helicopter transport of patients with COVID-19.** *Scand. J. Trauma Resusc. Emerg. Med.* 2020; 28:43Bredmose PP, Diczbalis M, Butterfield E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450877>
34. **COVID-19 in Singapore - a case series from primary care.** *Singapore Med J* 2020; Sim SZ, Teo SH, Kong JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460453>
35. **[Management of coronavirus disease 2019 (COVID-19): experiences from imported malaria control in China].** *Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi* 2020; 32:113-118Liu YB, Cao J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458598>

Mental – public health (47 articles)

1. **Uptrend in distress and psychiatric symptomatology in pregnant women during the COVID-19 pandemic.** *Acta Obstet Gynecol Scand* 2020; Berthelot N, Lemieux R, Garon-Bissonnette J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449178>
2. **Why all COVID-19 hospitals should have mental health professionals: The importance of mental health in a worldwide crisis!** *Asian J Psychiatr* 2020; 51:102147Grover S, Dua D, Sahoo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473537>
3. **Mental health and COVID-19 in Nepal: A case of a satellite clinic.** *Asian J Psychiatr* 2020; 53:102175Sharma P, Joshi D, Shrestha K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450492>
4. **COVID-19-related anxiety predicts somatic symptoms in the UK population.** *Br. J. Health Psychol.* 2020; Shevlin M, Nolan E, Owczarek M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458550>
5. **Depression and anxiety among adolescents during COVID-19: A cross-sectional study.** *Brain Behav Immun* 2020; Chen F, Zheng D, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464156>
6. **Correlation between immune response and self-reported depression during convalescence from COVID-19.** *Brain Behav Immun* 2020; Yuan B, Li W, Liu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464158>
7. **Impact of Public Health Interventions on Seasonal Influenza Activity During the SARS-CoV-2 Outbreak in Korea.** *Clin Infect Dis* 2020; Lee H, Lee H, Song KH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472687>
8. **COVID-19 Crisis: Early Observations on a Pandemic's Psychiatric Problems.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:675-681Fatke B, Hölzle P, Frank A, Förstl H.
9. **[Responsiveness and sustainability of psychiatric care in France during COVID-19 epidemic].** *Encephale* 2020; Bocher R, Jansen C, Gayet P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471705>
10. **[Suicidal behavior in light of COVID-19 outbreak: Clinical challenges and treatment perspectives].** *Encephale* 2020; Conejero I, Berrouguet S, Ducasse D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471707>
11. **Neuropsychiatric symptoms and quality of life in Spanish Alzheimer's disease patients during COVID-19 lockdown.** *Eur. J. Neurol.* 2020; Beatriz Lara B, Carnes A, Dakterzada F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449791>
12. **Stress resilience during the coronavirus pandemic.** *Eur. Neuropsychopharmacol.* 2020; Vinkers CH, van Amelsvoort T, Bisson JI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446705>
13. **Covid-19 and the Subsequent Lockdown Modified Dietary Habits of Almost Half the Population in an Italian Sample.** *Foods* 2020; 9Scarmozzino F, Visioli F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466106>

14. **Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement.** *Gen. Hosp. Psychiatry* 2020; 65:47-53 Beach SR, Praschan NC, Hogan C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470824>
15. **Public Mental Health as One of the Key Factors in Dealing with COVID-19.** *Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany))* 2020; 82:103-107 Haahda O, Gilan DA, Daiber A, Münzel T.
16. **The effects of COVID-19 on the health and socio-economic security of sex workers in Nairobi, Kenya: Emerging intersections with HIV.** *Glob Public Health* 2020:1-10 Kimani J, Adhiambo J, Kasiba R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459578>
17. **Impact of COVID-19 on the mental health of surgeons and coping strategies.** *Head Neck* 2020; 42:1-10 Balasubramanian A, Paleri V, Bennett R, Paleri V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462783>
18. **COVID-19 pandemic, socioeconomic crisis and human stress in resource-limited settings: A case from Bangladesh.** *Heliyon* 2020; 6:e04063 Shammi M, Bodrud-Doza M, Towfiqul Islam ARM, Rahman MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462098>
19. **Compliance and Psychological Impact of Quarantine in Children and Adolescents due to Covid-19 Pandemic.** *Indian J Pediatr* 2020; 87:103-107 Saurabh K, Ranjan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472347>
20. **Psychological status and behavior changes of the public during the COVID-19 epidemic in China.** *Infect Dis Poverty* 2020; 9:58 Liu X, Luo WT, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471513>
21. **Digital technology can revolutionize mental health services delivery: The COVID-19 crisis as a catalyst for change.** *Int. J. Eat. Disord.* 2020; Taylor CB, Fitzsimmons-Craft EE, Graham AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449523>
22. **Conducting eating disorders research in the time of COVID-19: A survey of researchers in the field.** *Int. J. Eat. Disord.* 2020; Weissman RS, Klump KL, Rose J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449555>
23. **Depression and Anxiety in Hong Kong during COVID-19.** *Int J Environ Res Public Health* 2020; 17:1-10 Choi EPH, Hui BPH, Wan EYF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466251>
24. **The Psychological Impact of Confinement Linked to the Coronavirus Epidemic COVID-19 in Algeria.** *Int J Environ Res Public Health* 2020; 17:1-10 Madani A, Boutebal SE, Bryant CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455550>
25. **A Multidimensional Model of Public Health Approaches Against COVID-19.** *Int J Environ Res Public Health* 2020; 17:1-10 Nazir M, Hussain I, Tian J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466581>
26. **Changes in Provision of Psychotherapy in the Early Weeks of the COVID-19 Lockdown in Austria.** *Int J Environ Res Public Health* 2020; 17:1-10 Probst T, Stippel P, Pieh C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471295>
27. **The Mental Health Burden of the COVID-19 Pandemic on Physical Therapists.** *Int J Environ Res Public Health* 2020; 17:1-10 Yang S, Kwak SG, Ko EJ, Chang MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466164>
28. **Domestic violence amid COVID-19.** *Int J Gynaecol Obstet* 2020; 142:1-10 Anurudran A, Yared L, Comrie C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472696>
29. **Mental Health Impacts of COVID-19 in Ireland and the Need for a Secondary Care, Mental Health Service Response.** *Ir. J. Psychol. Med.* 2020:1-18 O'Connor K, Wrigley M, Jennings R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456713>
30. **The psycho-social effects of COVID-19 on Italian adolescents' attitudes and behaviors.** *Ital. J. Pediatr.* 2020; 46:69 Buzzi C, Tucci M, Ciprandi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448323>
31. **Impact of the COVID-19 Pandemic on Mental Health and Social Support among Adult Egyptians.** *J. Community Health* 2020; 45:1-10 El-Zoghby SM, Soltan EM, Salama HM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468155>
32. **The Emergence of COVID-19 in the U.S.: A Public Health and Political Communication Crisis.** *J. Health Polit. Policy Law* 2020; 45:1-10 Gollust SE, Nagler RH, Fowler EF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464658>
33. **Federalism Complicates the Response to the COVID-19 Health and Economic Crisis: What Can Be Done?** *J. Health Polit. Policy Law* 2020; 45:1-10 Huberfeld N, Gordon SH, Jones DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464666>
34. **Democracy, Capacity, and Coercion in Pandemic Response-COVID 19 in Comparative Political Perspective.** *J. Health Polit. Policy Law* 2020; 45:1-10 Kavanagh MM, Singh R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464665>
35. **Health Equity, Social Policy, and Promoting Recovery from COVID-19.** *J. Health Polit. Policy Law* 2020; 45:1-10 Lynch J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464651>
36. **Disaster Preparedness and Social Justice in a Public Health Emergency.** *J. Health Polit. Policy Law* 2020; 45:1-10 Pollack HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464639>
37. **Child protection in the time of COVID-19.** *J. Paediatr. Child Health* 2020; 56:1-10 S SST, Griffiths G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468616>
38. **The impact of having inadequate safety equipment on mental health.** *Occup. Med. (Lond.)* 2020; 70:1-10 Simms A, Fear NT, Greenberg N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449770>
39. **Impact of coronavirus pandemic in appointments and anxiety/concerns of patients regarding orthodontic treatment.** *Orthod. Craniofac. Res.* 2020; 23:1-10 Cotrin PP, Peloso RM, Oliveira RC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449999>
40. **Public and Private Health Services: Wait Times for Health Services and the Risk of Inequality from the Italian Perspective.** *Popul Health Manag* 2020; 16:1-10 Cioffi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466717>
41. **Accountability to Population Health in the COVID-19 Pandemic: Designing Health Care Delivery Within a Social Responsibility Framework.** *Popul Health Manag* 2020; 16:1-10 Cutter CM, Nelson C, Abir M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463721>
42. **Rapid Conversion of an Outpatient Psychiatric Clinic to a 100% Virtual Telepsychiatry Clinic in Response to COVID-19.** *Psychiatr. Serv.* 2020:appips202000230 Yellowlees P, Nakagawa K, Pakyurek M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460683>

43. **University students' mental health amidst the COVID-19 quarantine in Greece.** *Psychiatry Res* 2020; 290:113111Kaparounaki CK, Patsali ME, Mousa DV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450416>
44. **Clinically significant fear and anxiety of COVID-19: A psychometric examination of the Coronavirus Anxiety Scale.** *Psychiatry Res* 2020; 290:113112Lee SA, Mathis AA, Jobe MC, Pappalardo EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460185>
45. **[About public health communication strategies and campaigns: what do you know about 2019-nCoV?].** *Rev. Esp. Salud Publica* 2020; 94:e1-e2Billbatua Andres J, Mudaber J, Jimenez-Vargas D, Arrieta Angulo B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452469>
46. **[Application and thinking of health standards related to public health in prevention and control of coronavirus disease 2019].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:E068Xu X, Jiang YC, Yang YQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455512>
47. **[Application and thinking of health standards related to medical care and health information etc. in prevention and control of COVID-19].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:E069Xu X, Yang YQ, Jiang YC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455513>

Meta-analyses - systematic reviews (5 articles)

1. **Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.** *Clin Microbiol Infect* 2020; Rodrigo C, Fernando SD, Rajapakse S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470568>
2. **The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis.** *Crit Care* 2020; 24:255Aziz M, Fatima R, Lee-Smith W, Assaly R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456658>
3. **Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis.** *Int J Public Health* 2020; Jain V, Yuan JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451563>
4. **Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.** *J Clin Med* 2020; 9Ang L, Song E, Lee HW, Lee MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456123>
5. **Co-infections in people with COVID-19: a systematic review and meta-analysis.** *J Infect* 2020; Lansbury L, Lim B, Baskaran V, Lim WS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473235>

Mortality (9 articles)

1. **Age-related difference in the rate of COVID-19 mortality in women versus men.** *Am J Obstet Gynecol* 2020; Cagnacci A, Xholli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460973>
2. **Excess out-of-hospital deaths during COVID-19 outbreak: evidence of pulmonary embolism as a main determinant.** *Eur J Heart Fail* 2020; Benzakoun J, Hmeydia G, Delabarde T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463538>
3. **[Impact of COVID-19 on mortality in the autonomous community of Castilla y Leon (Spain)].** *Gac. Sanit.* 2020; Ochoa Sangrador C, Garmendia Leiza JR, Perez Boillos MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446595>
4. **Deaths in nine regions of Italy in February/March 2020: "Mortality Excess Loupe" for SARS-CoV-2/COVID-19-Epidemiology in Germany.** *Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))* 2020; Morfeld P, Erren TC.
5. **Maternal mortality from COVID-19 in Mexico.** *Int J Gynaecol Obstet* 2020; Lumbreras-Marquez MI, Campos-Zamora M, Lizaola-Diaz de Leon H, Farber MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473603>
6. **COVID-19 Pandemic: Marked Global Disparities in Fatalities According to Geographic Location and Universal Health Care.** *Int J MCH AIDS* 2020; 9:213-216Dongarwar D, Saliu HM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461818>
7. **Excess mortality from COVID-19: a commentary on the Italian experience.** *Int J Public Health* 2020; Pasquariello P, Stranges S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468219>
8. **Analysis of Mortality in Patients With COVID-19: Clinical and Laboratory Parameters.** *Open Forum Infect Dis* 2020; 7:ofaa152Tian S, Liu H, Liao M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457924>
9. **COVID-19 Waves: Importance of Accumulative Mortality per Million Inhabitants.** *Tohoku J. Exp. Med.* 2020; 251:47-49Delgado CA, Shimabuku RL, Chiroque-Solano PM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461502>

On-line – IT – Apps (25 articles)

1. **YouTube as a source of information on COVID-19 and rheumatic disease link.** *Clin Rheumatol* 2020; Kocyyigit BF, Akaltun MS, Sahin AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447603>
2. **Social Media Data Analytics on Telehealth During the COVID-19 Pandemic.** *Cureus* 2020; 12:e7838Massaad E, Cherfan P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32467813>
3. **Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy.** *Dermatol Ther* 2020:e13495Brunasso AMG, Massone C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458588>
4. **Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.** *EMBO Mol Med* 2020; Stebbing J, Krishnan V, de Bono S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473600>
5. **Telemedicine in nursing homes during the COVID-19 outbreak: A star is born (again).** *Geriatr Gerontol Int* 2020; Cormi C, Chrusciel J, Laplanche D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462676>

6. **Tele-consultations and electronic medical records driven remote patient care: Responding to the COVID-19 lockdown in India.** *Indian J Ophthalmol* 2020; 68:1007-1012 Das AV, Rani PK, Vaddavalli PK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461415>
7. **Digital technology can revolutionize mental health services delivery: The COVID-19 crisis as a catalyst for change.** *Int. J. Eat. Disord.* 2020; Taylor CB, Fitzsimmons-Craft EE, Graham AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449523>
8. **Healthcare information on YouTube: Pregnancy and COVID-19.** *Int J Gynaecol Obstet* 2020; Yuksel B, Cakmak K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471005>
9. **Deep learning COVID-19 detection bias: accuracy through artificial intelligence.** *Int. Orthop.* 2020; Vaid S, Kalantar R, Bhandari M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462314>
10. **Virtualised care and COVID-19.** *Ir. J. Med. Sci.* 2020; MF OR, Merghani K, Sheehan E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468414>
11. **An AI approach to COVID-19 infection risk assessment in virtual visits: a case report.** *J Am Med Inform Assoc* 2020; Obeid JS, Davis M, Turner M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449766>
12. **Veterans' Response to an Automated Text Messaging Protocol During the COVID-19 Pandemic.** *J Am Med Inform Assoc* 2020; Saleem JJ, Read JM, Loehr BM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470974>
13. **Benefits of Technology in the Age of COVID-19 and Diabetes. . . Mobile Phones From a Rwanda Perspective.** *J. Diabetes Sci. Technol.* 2020:1932296820930032Krisiunas E, Sibomana L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460536>
14. **Diabetes and Technology in the Covid-19 Pandemic Crisis.** *J. Diabetes Sci. Technol.* 2020:1932296820929385Spanakis EK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460544>
15. **COVID-19, Type 1 Diabetes Clinical Practice, Research, and Remote Medical Care: A View From the Land Down-Under.** *J. Diabetes Sci. Technol.* 2020:1932296820929708Venkatesh N, Paldus B, Lee MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468858>
16. **Role of biological Data Mining and Machine Learning Techniques in Detecting and Diagnosing the Novel Coronavirus (COVID-19): A Systematic Review.** *J Med Syst* 2020; 44:122Albahri AS, Hamid RA, Alwan JK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451808>
17. **Teleneurology during the COVID-19 pandemic: A step forward in modernizing medical care.** *J Neurol Sci* 2020; 414:116930Roy B, Nowak RJ, Roda R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460041>
18. **COVID-19: Putting the General Data Protection Regulation to the Test.** *JMIR Public Health Surveill* 2020; 6:e19279McLennan S, Celi LA, Buyx A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449686>
19. **Implementation and analysis of a telephone support service during COVID-19.** *Occup. Med. (Lond.)* 2020; Matthewson J, Tiplady A, Gerakios F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449754>
20. **Video Conferencing in the Intravitreal Injection Clinic in Response to the COVID-19 Pandemic.** *Ophthalmol Ther* 2020; Saedon H, Gould G, Begum M, Aslam TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451906>
21. **A telemedicina lehetosegei a COVID-19-pandemia kapcsan a nemzetkozi es a magyarorszagi tapasztalatok es ajanlasok tukreben.** *Orv. Hetil.* 2020; 161:983-992Gyorffy Z, Bekasi S, Szathmari-Meszaros N, Nemeth O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469844>
22. **Possibilities of telemedicine regarding the COVID-19 pandemic in light of the international and Hungarian experiences and recommendations.** *Orv. Hetil.* 2020; 161:983-992Gyorffy Z, Bekasi S, Szathmari-Meszaros N, Nemeth O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469844>
23. **Telemedicine During the COVID-19 Pandemic: A Pediatric Otolaryngology Perspective.** *Otolaryngol Head Neck Surg* 2020:194599820931827Maurrasse SE, Rastatter JC, Hoff SR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450755>
24. **Rapid Conversion of an Outpatient Psychiatric Clinic to a 100% Virtual Telepsychiatry Clinic in Response to COVID-19.** *Psychiatr. Serv.* 2020:appips202000230Yellowlees P, Nakagawa K, Pakyurek M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460683>
25. **Telemedicine for Outpatient Neurosurgical Oncology Care: Lessons Learned for the Future During the COVID-19 Pandemic.** *World Neurosurg* 2020; Daggubati LC, Eichberg DG, Ivan ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450309>

Other – Miscellaneous (31 articles)

1. **Distributive justice during the COVID-19 pandemic in Australia.** *ANZ J Surg* 2020; Fisher OM, Brown KG, Coker DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452147>
2. **How did "flatten the curve" become "flatten the economy?" A perspective from the United States of America.** *Asian J Psychiatr* 2020; 51:102165Jenson HB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464513>
3. **The Urgent Need for Medicare Reimbursement for Home Infusion Antibiotics amidst a Pandemic.** *Clin Infect Dis* 2020; Streifel AC, Sikka MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463077>
4. **Electronic nicotine delivery systems (ECs) and COVID-19: the perfect storm for young consumers.** *Clin. Transl. Oncol.* 2020; Pino LE, Triana I, Perez C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447647>
5. **Initial evidence on the relationship between the coronavirus pandemic and crime in the United States.** *Crime Sci* 2020; 9:6Ashby MPJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455094>
6. **The explosion in scabies cases during COVID-19 pandemic.** *Dermatol Ther* 2020; Kutlu O, Aktas H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447797>
7. **Legal Issues of Resource Allocation in the COVID-19 Pandemic - Between Utilitarianism and Life Value Indifference.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:687-692Hübner J, Schewe DM, Katalinic A, Frielitz FS.
8. **Struggling to get started.** *Elife* 2020; 9Tay A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459175>
9. **Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration.** *ESMO Open* 2020; 5Palmieri C, Palmer D, Openshaw PJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457054>

10. **The role of head and neck cancer advocacy organizations during the COVID-19 pandemic.** Head Neck 2020; Yan F, Rauscher E, Hollinger A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468607>
11. **The Impact of COVID-19 on Tourist Satisfaction with B&B in Zhejiang, China: An Importance-Performance Analysis.** Int J Environ Res Public Health 2020; 17Hong Y, Cai G, Mo Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466326>
12. **Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of COVID-19 Infected Individuals: A Narrative Review From the World Association of Vibration Exercise Experts (WAVex) Panel.** Int J Environ Res Public Health 2020; 17Sanudo B, Seixas A, Gloeckl R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455961>
13. **"COVID-19: Results of a national survey of United Kingdom healthcare professionals' perceptions of current management strategy - a cross-sectional questionnaire study".** Int J Surg 2020; Iqbal MR, Chaudhuri A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447002>
14. **Loud and silent epidemics in the third millennium: tuning-up the volume.** Int. Orthop. 2020; Romano CL, Drago L, Del Sel H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449044>
15. **Willingness of Chinese nurses to practice in Hubei combating the coronavirus disease 2019 epidemic: A cross-sectional study.** J. Adv. Nurs. 2020; Gan X, Shi Z, Ying Chair S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449187>
16. **COVID-19 pandemic and home-based physical activity.** J Allergy Clin Immunol Pract 2020; Carvalho VO, Gois CO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470443>
17. **The impact of Covid-19 pandemic on corporate social responsibility and marketing philosophy.** J Bus Res 2020; 116:176-182He H, Harris L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457556>
18. **The COVID-19 Pandemic: A "Tech"-tonic Shift Toward Virtual Diabetes Care.** J. Diabetes Sci. Technol. 2020:1932296820929719Ahn DT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450726>
19. **Professional autonomy and liability of the resident doctor: Between the hammer and the anvil.** J. Forensic Leg. Med. 2020; 72:101965Cioffi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452455>
20. **COVID-19 in forensic medicine unit personnel: Observation from Thailand.** J. Forensic Leg. Med. 2020; 72:101964Sriwijitalai W, Wiwanitkit V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452454>
21. **Racism and the Political Economy of COVID-19: Will We Continue to Resurrect the Past?** J. Health Polit. Policy Law 2020; Bailey ZD, Moon JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464657>
22. **Nowhere to hide: The significant impact of coronavirus disease 2019 (COVID-19) measures on elite and semi-elite South African athletes.** J. Sci. Med. Sport 2020; Pillay L, Janse van Rensburg DCC, Jansen van Rensburg A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448749>
23. **COVID-19, quarantine, and atopic dermatitis.** Med. Hypotheses 2020; 143:109852Patrino C, Nistico SP, Fabbrocini G, Napolitano M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447099>
24. **COVID-19 in the UK and Occupational Health and Safety: Predictable not Inevitable Failures by Government, and Trade Union and Nongovernmental Organization Responses.** New Solut. 2020:1048291120929763Watterson A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448036>
25. **Tobacco Use Patterns in five countries during the COVID-19 Lockdown.** Nicotine Tob Res 2020; Yach D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459837>
26. **Metabolic Impacts of Confinement during the COVID-19 Pandemic Due to Modified Diet and Physical Activity Habits.** Nutrients 2020; 12Martinez-Ferran M, de la Guia-Galipienso F, Sanchis-Gomar F, Pareja-Galeano H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466598>
27. **Onkológiai beteg tervezett PET/CT vizsgálatá soran veletlenszerűen felfedezett COVID-19-betegség.** Orv. Hetil. 2020; 161:971-976Czibor S, Kristof E, Kecskes K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453695>
28. **Procoagulatio, hypercoagulatio es fibrinolysis "shut down" kimutatása ClotPro(R) vizsgálóasztikus tesztek segítségével COVID-19-betegekben.** Orv. Hetil. 2020; 161:899-907Zatroch I, Smudla A, Babik B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453702>
29. **An Otolaryngologist Redeployed to a COVID-19 Intensive Care Unit: Lessons Learned.** Otolaryngol Head Neck Surg 2020:194599820931819Dhar SI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450756>
30. **How Strong Is the Duty to Treat in a Pandemic? Ethics in Practice: Point-Counterpoint.** Otolaryngol Head Neck Surg 2020:194599820930246Redmann AJ, Manning A, Kennedy A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450750>
31. **No Participant Left Behind: Conducting Science During COVID-19.** Trends Cogn. Sci. 2020; Lourenco SF, Tasimi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451239>

Pathology (5 articles)

1. **Molecular Detection of SARS-CoV-2 Infection in FFPE Samples and Histopathologic Findings in Fatal SARS-CoV-2 Cases.** Am J Clin Pathol 2020; Sekulic M, Harper H, Nezami BG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451533>
2. **Speeding tumor genotyping during the SARS-CoV-2 outbreak through liquid biopsy.** Cancer 2020; Rolfo C, Russo A, de Miguel-Perez D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472948>
3. **SARS-CoV-2 Persisted in Lung Tissue Despite Disappearance in Other Clinical Samples.** Clin Microbiol Infect 2020; Zhao Y, Xia Z, Liang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447048>
4. **Graphene-Based Strategies in Liquid Biopsy and in Viral Diseases Diagnosis.** Nanomaterials (Basel) 2020; 10Cordaro A, Neri G, Sciortino MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466536>
5. **Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients.** Ocul Immunol Inflamm 2020:1-5Casagrande M, Fitzek A, Puschel K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469258>

Protection (38 articles)

1. **Face Mask-induced Itch: A Self-questionnaire Study of 2,315 Responders During the COVID-19 Pandemic.** Acta Derm. Venereol. 2020; Szepletowski JC, Matusiak L, Szepletowska M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449781>

2. **Pretreated household materials carry similar filtration protection against pathogens when compared with surgical masks.** *Am. J. Infect. Control* 2020; Carnino JM, Ryu S, Ni K, Jin Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464294>
3. **Infection control practices in children during COVID-19 pandemic: differences from adults.** *Am. J. Infect. Control* 2020; Devrim I, Bayram N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464297>
4. **The impact of novel coronavirus SARS-CoV-2 among healthcare workers in hospitals: An aerial overview.** *Am. J. Infect. Control* 2020; Xiang B, Li P, Yang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464298>
5. **Thinking outside the (acrylic) box: a framework for the local use of custom-made medical devices.** *Anaesthesia* 2020; Turner MC, Duggan LV, Glezerson BA, Marshall SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470144>
6. **Ultra-portable low-cost improvised powered air-purifying respirator: feasibility study.** *Br J Anaesth* 2020; Khoo D, Yen CC, Chow WT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446500>
7. **Comparison of three tracheal intubation methods for reducing droplet spread for use in COVID-19 patients.** *Br J Anaesth* 2020; Yang SS, Zhang M, Chong JJR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448441>
8. **COVID-19: Safe Guidelines for Breast Imaging During the Pandemic.** *Can Assoc Radiol J* 2020;846537120928864Seely JM, Scaranelo AM, Yong-Hing C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452700>
9. **Surgical mask partition reduces the risk of non-contact transmission in a golden Syrian hamster model for Coronavirus Disease 2019 (COVID-19).** *Clin Infect Dis* 2020; Chan JF, Yuan S, Zhang AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472679>
10. **Use of an antiviral filter attached to a pleural drain bottle to prevent aerosol contamination with SARS-CoV-2.** *Clin Med (Lond)* 2020; Akhtar MR, Ricketts W, Fotheringham T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457134>
11. **SARS-CoV-2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit.** *Clin Microbiol Infect* 2020; Colaneri M, Seminari E, Novati S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450255>
12. **Surgical mask dermatitis caused by formaldehyde (releasers) during the COVID-19 pandemic.** *Contact Dermatitis* 2020; Aerts O, Dendooven E, Foubert K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468589>
13. **Universal mobile protection system for aerosol-generating medical interventions in COVID-19 patients.** *Crit Care* 2020; 24:264Straube F, Wendtner C, Hoffmann E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456661>
14. **Knowledge, Attitude, and Practices of Healthcare Workers Regarding the Use of Face Mask to Limit the Spread of the New Coronavirus Disease (COVID-19).** *Cureus* 2020; 12:e7737Kumar J, Katto MS, Siddiqui AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455057>
15. **Control measures to prevent Coronavirus disease 2019 COVID-19 pandemic in endoscopy centers: a multi-centre study.** *Dig Endosc* 2020; Huang Q, Liu G, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473036>
16. **Nurse Infected with Covid-19 from a Provisional Dengue Patient.** *Emerg Microbes Infect* 2020;1-5Prasitsirikul W, Pongpirul K, Pongpirul WA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458742>
17. **Incidentally discovered COVID-19 in low-suspicion patients-a threat to front line health care workers.** *Emerg Radiol* 2020; Xiao N, Abboud S, McCarthy DM, Parekh N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449100>
18. **Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19.** *Eur Arch Otorhinolaryngol* 2020; Pianta L, Vinciguerra A, Bertazzoni G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449022>
19. **Management of a delivery suite during the COVID-19 epidemic.** *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2020; Qi H, Chen M, Luo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466867>
20. **Manufacturing and supply of face shields in hospital operation in case of unclear and confirmed COVID-19 infection status of patients.** *Eur. J. Trauma Emerg. Surg.* 2020; Neijhoft J, Viertmann T, Meier S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462375>
21. **COVID-19 infections among healthcare workers exposed to a patient with a delayed diagnosis of COVID-19.** *Infect Control Hosp Epidemiol* 2020;1-9Baker MA, Rhee C, Fiumara K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456720>
22. **Letter to editor - Can universal masking help with our recovery from the COVID-19 pandemic?** *Int J Surg* 2020; Chiang CH, Chiang CH, Chiang CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450263>
23. **Commentary on: A Novel solution to the PPE crisis during the Coronavirus pandemic (COVID-19).** *Int J Surg* 2020; Syed DS, Malik MS, Ominu-Evbota K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470595>
24. **AVOIDING HEALTH WORKER INFECTION AND CONTAINING THE CORONAVIRUS DISEASE 2019 PANDEMIC: Perspectives from the frontline in Wuhan.** *Int J Surg* 2020; Tang LH, Tang S, Chen XL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454250>
25. **Providing evidence on the ongoing health care workers' mask debate.** *Intern Emerg Med* 2020; Tsilingiris D, Papatheodoridi M, Kapelios CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468509>
26. **New York City COVID-19 resident physician exposure during exponential phase of pandemic.** *J. Clin. Invest.* 2020; Breazzano MP, Shen J, Abdelhakim AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463802>
27. **The Ocular Manifestations and Transmission of COVID-19: Recommendations for Prevention.** *J. Emerg. Med.* 2020; Dockery DM, Rowe SG, Murphy MA, Krzystolik MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456959>
28. **Sterilization plan of the used metered dose inhalers (MDI) to avoid wastage amid COVID-19 pandemic drug shortage.** *J Pharm Policy Pract* 2020; 13:19Elbeddini A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454983>
29. **A Structured Approach for Safely Reintroducing Bariatric Surgery in a COVID-19 Environment.** *Obes. Surg.* 2020; Daigle CR, Augustin T, Wilson R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458364>
30. **The impact of having inadequate safety equipment on mental health.** *Occup. Med. (Lond.)* 2020; Simms A, Fear NT, Greenberg N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449770>

31. **Ventilated Upper Airway Endoscopic Endonasal Procedure Mask: Surgical Safety in the COVID-19 Era.** *Oper Neurosurg (Hagerstown)* 2020; Helman SN, Soriano RM, Tomov ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472685>
32. **Digital prosthetic workflow during COVID-19 pandemic to limit infection risk in dental practice.** *Oral Dis* 2020; Papi P, Di Murro B, Penna D, Pompa G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460440>
33. **Safety and Prognosis in Percutaneous vs Surgical Tracheostomy in 27 Patients With COVID-19.** *Otolaryngol Head Neck Surg* 2020:194599820931801Riestra-Ayora J, Yanes-Diaz J, Penuelas O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450761>
34. **Airborne Aerosol Generation During Endonasal Procedures in the Era of COVID-19: Risks and Recommendations.** *Otolaryngol Head Neck Surg* 2020:194599820931805Workman AD, Jafari A, Welling DB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452739>
35. **COVID-19 - More Lung Pocus and Sparing Use of Stethoscope, Chest X-Ray and Lung CT.** *Praxis* 2020:1-9Osterwalder J.
36. **Safe extubation during the COVID-19 pandemic.** *Respir. Med.* 2020; 170:106038Kangas-Dick AW, Swearingen B, Wan E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469731>
37. **The risk of COVID-19 transmission by laparoscopic smoke may be lower than for laparotomy: a narrative review.** *Surg. Endosc.* 2020; Mintz Y, Arezzo A, Boni L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458289>
38. **Preventing transmission among operating room staff during COVID-19 pandemic: the role of the Aerosol Box and other personal protective equipment.** *Updates Surg.* 2020; Bianco F, Incollingo P, Grossi U, Gallo G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449034>

Pulmonary disease (4 articles)

1. **COVID-19 pneumonia: phenotype assessment requires bedside tools.** *Crit Care* 2020; 24:272Zhao Z, Kung WH, Chang HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471449>
2. **Inside the lungs of COVID-19 disease.** *Int. J. Legal Med.* 2020; Aguiar D, Lohrinus JA, Schibler M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458044>
3. **COVID-19 and asthma: To have or not to have T2 inflammation makes a difference?** *Pulmonology* 2020; Morais-Almeida M, Bousquet J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466999>
4. **[Clinical feature changes of a COVID-19 patient from mild to critical condition and cardiopulmonary pathological results].** *Zhonghua Xin Xue Guan Bing Za Zhi* 2020; 48:E018Jiang SW, Gao H, Wu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455515>

Renal disease (9 articles)

1. **The impact of the COVID-19 pandemic on renal transplantation in the UK.** *Clin Med (Lond)* 2020; Sharma V, Shaw A, Lowe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457133>
2. **Presentation and Outcomes of Patients with ESKD and COVID-19.** *J Am Soc Nephrol* 2020; Valeri AM, Robbins-Juarez SY, Stevens JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32467113>
3. **COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis.** *Kidney Blood Press. Res.* 2020:1-6Perna AF, Capolongo G, Trepiccione F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450560>
4. **A view from the front line of the COVID-19 war.** *Kidney Int* 2020; Carrara C, Cappelletti L, Portalupi V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451077>
5. **Managing the COVID-19 pandemic: international comparisons in dialysis patients.** *Kidney Int* 2020; Kliger AS, Cozzolino M, Jha V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471637>
6. **High prevalence of asymptomatic COVID-19 in haemodialysis: learning day by day in the first month of the COVID-19 pandemic.** *Nefrologia* 2020; Albalade M, Arribas P, Torres E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456944>
7. **[Renal Monomorphology in COVID-19 with Acute Renal Insufficiency].** *Praxis (Bern 1994)* 2020:1-5Tuma J, Neugebauer F, Rohacek M, Serra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469263>
8. **[COVID-19 and cardiovascular and kidney disease: Where are we? Where are we going?].** *Semerger* 2020; Pallares Carratala V, Gorriiz-Zambrano C, Morillas Arino C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448633>
9. **Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab.** *Transpl Infect Dis* 2020:e13334Lauterio A, Valsecchi M, Santambrogio S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449235>

Reviews (23 articles)

1. **Review of trials currently testing treatment and prevention of COVID-19.** *Clin Microbiol Infect* 2020; Fragkou PC, Belhadi D, Peiffer-Smadja N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454187>
2. **Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.** *Clin Rheumatol* 2020; Dai J, Xiong Y, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451729>
3. **Treatment algorithm for COVID-19: a multidisciplinary point of view.** *Clin Rheumatol* 2020; Galluccio F, Ergonenc T, Garcia Martos A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472459>
4. **A Review of Neurological Complications of COVID-19.** *Cureus* 2020; 12:e8192Sheraton M, Deo N, Kashyap R, Surani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455089>
5. **Cutaneous manifestations of COVID-19: A review of the published literature.** *Dermatol Ther* 2020; Elmas OF, Demirbas A, Ozyurt K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458546>
6. **Coronavirus disease (COVID-19): An updated review based on current knowledge and existing literature for dermatologists.** *Dermatol Ther* 2020; Kaur I, Sharma A, Jakhar D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447820>
7. **The new corona virus: many unanswered questions.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:641Middeke M.

8. **Postintubation Dysphagia During COVID-19 Outbreak-Contemporary Review.** *Dysphagia* 2020; Frajkova Z, Tedla M, Tedlova E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468193>
9. **Profile and quality of published reviews on COVID-19.** *Eur. J. Clin. Invest.* 2020:e13293Pericas JM, Torrallardona-Murphy O, Arenas A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473068>
10. **Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review.** *Infect Dis Ther* 2020; Fajgenbaum DC, Khor JS, Gorzewski A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462545>
11. **Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence.** *Int J Clin Pract* 2020:e13557Yousefifard M, Zali A, Zarghi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460369>
12. **Covid-19 Pandemic: What Changes for Dentists and Oral Medicine Experts? A Narrative Review and Novel Approaches to Infection Containment.** *Int J Environ Res Public Health* 2020; 17Bizzoca ME, Campisi G, Muzio LL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471083>
13. **The COVID-19 pandemic: is our medicine still evidence-based?** *Ir. J. Med. Sci.* 2020; Deana C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468413>
14. **COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease.** *J. Cell. Physiol.* 2020; Sheervalilou R, Shirvaliloo M, Dadashzadeh N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452539>
15. **A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.** *J. Clin. Pharmacol.* 2020; Ren YR, Golding A, Sorbello A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469437>
16. **Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review.** *J Eur Acad Dermatol Venereol* 2020; Docampo-Simon A, Sanchez-Pujol MJ, Juan-Carpena G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452545>
17. **COVID-19 and pregnancy - where are we now? A review.** *J. Perinat. Med.* 2020; Rajewska A, Mikolajek-Bedner W, Lebdowicz-Knul J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452195>
18. **Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review.** *Life Sci* 2020:117839KaviyarasiRenu, Prasanna PL, Abilash VG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450165>
19. **Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review.** *Life Sci* 2020; 255:117839Renu K, Prasanna PL, Valsala Gopalakrishnan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450165>
20. **Care of ophthalmological patients during the COVID-19 pandemic: A rapid scoping review.** *Medwave* 2020; 20:e7902Vargas-Peirano M, Navarrete P, Diaz T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469854>
21. **COVID-19 and NSAIDs: A Narrative Review of Knowns and Unknowns.** *Pain Ther* 2020; Pergolizzi JV, Jr., Varrassi G, Magnusson P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447629>
22. **Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.** *Viruses* 2020; 12Younes N, Al-Sadeq DW, Al-Jighefee H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466458>
23. **A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions.** *World J. Urol.* 2020; Chan VW, Chiu PK, Yee CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462305>

Risk factors (36 articles)

1. **An update on ACE2 amplification and its therapeutic potential.** *Acta Physiol. (Oxf.)* 2020:e13513Marquez A, Wysocki J, Pandit J, Batlle D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469114>
2. **Why does COVID-19 disproportionately affect older people?** *Aging (Albany NY)* 2020; 12Mueller AL, McNamara MS, Sinclair DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470948>
3. **Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19.** *Am J Emerg Med* 2020; Wilkerson RG, Adler JD, Shah NG, Brown R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471783>
4. **Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis.** *Am. J. Epidemiol.* 2020; Risch HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458969>
5. **Age-related difference in the rate of COVID-19 mortality in women versus men.** *Am J Obstet Gynecol* 2020; Cagnacci A, Xholli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460973>
6. **Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes.** *Am J Physiol Endocrinol Metab* 2020; Korakas E, Ikonomidis I, Kousathana F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459524>
7. **Angiopietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients.** *Angiogenesis* 2020; Smadja DM, Guerin CL, Chocron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458111>
8. **Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.** *Arch Med Res* 2020; Assandri R, Buscarini E, Canetta C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471703>
9. **Impact of sex and gender on COVID-19 outcomes in Europe.** *Biol. Sex Differ.* 2020; 11:29Gebhard C, Regitz-Zagrosek V, Neuhauser HK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450906>
10. **An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19.** *Clin Chim Acta* 2020; Saadat M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454047>
11. **Predictors for Severe COVID-19 Infection.** *Clin Infect Dis* 2020; Bhargava A, Fukushima EA, Levine M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472676>
12. **The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis.** *Crit Care* 2020; 24:255Aziz M, Fatima R, Lee-Smith W, Assaly R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456658>
13. **Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.** *Diabetes Metab Syndr* 2020; 14:713-714Erol A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470851>
14. **Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.** *Diabetologia* 2020; Cariou B, Hadjadj S, Wargny M *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472191>
15. **Overdose and risk factors for coronavirus disease 2019.** *Drug Alcohol Depend.* 2020; 212:108047Slaunwhite AK, Gan WQ, Xavier C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447172>
 16. **Correlation between environmental pollution indicators and COVID-19 pandemic: A brief study in Californian context.** *Environ. Res.* 2020; 187:109652Bashir MF, Ma BJ, Bilal *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454308>
 17. **The gendered impact of coronavirus disease (COVID-19): do estrogens play a role?** *Eur. J. Contracept. Reprod. Health Care* 2020;1-2Grandi G, Facchinetti F, Bitzer J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469251>
 18. **The lethal sex gap: COVID-19.** *Immun. Ageing* 2020; 17:13Marquez EJ, Trowbridge J, Kuchel GA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457811>
 19. **Smoking-Mediated Upregulation of the Androgen Pathway Leads to Increased SARS-CoV-2 Susceptibility.** *Int J Mol Sci* 2020; 21Chakladar J, Shende N, Li WT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455539>
 20. **Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis.** *Int J Public Health* 2020; Jain V, Yuan JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451563>
 21. **An AI approach to COVID-19 infection risk assessment in virtual visits: a case report.** *J Am Med Inform Assoc* 2020; Obeid JS, Davis M, Turner M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449766>
 22. **A theory on SARS-COV-2 susceptibility: reduced TLR7-activity as a mechanistic link between men, obese and elderly.** *J Biol Regul Homeost Agents* 2020; 34Englmeier L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456409>
 23. **Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.** *J. Cutan. Med. Surg.* 2020;1203475420929250Nassim D, Jfri A, Litvinov IV, Netchiporouk E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449619>
 24. **APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort.** *J Gerontol A Biol Sci Med Sci* 2020; Kuo CL, Pilling LC, Atkins JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451547>
 25. **Importance of timely management of patients in reducing fatality rate of coronavirus disease 2019.** *J Infect Public Health* 2020; Peng Y, Xu B, Sun B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451257>
 26. **Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva.** *J Korean Med Sci* 2020; 35:e195Yoon JG, Yoon J, Song JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449329>
 27. **Early risk factors of the exacerbation of Coronavirus disease 2019 pneumonia.** *J Med Virol* 2020; Wang CZ, Hu SL, Wang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470167>
 28. **COVID-19 related neuroimaging findings: A signal of thromboembolic complications and a strong prognostic marker of poor patient outcome.** *J Neurol Sci* 2020; 414:116923Jain R, Young M, Dogra S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447193>
 29. **The case of Complement activation in COVID-19 multiorgan impact.** *Kidney Int* 2020; Noris M, Benigni A, Remuzzi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461141>
 30. **Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.** *Nutr. Metab. Cardiovasc. Dis.* 2020; Li M, Dong Y, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456948>
 31. **Obesity is associated with worse outcomes in COVID-19: Analysis of Early Data From New York City.** *Obesity (Silver Spring)* 2020; Hajifathalian K, Kumar S, Newberry C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470210>
 32. **Analysis of Mortality in Patients With COVID-19: Clinical and Laboratory Parameters.** *Open Forum Infect Dis* 2020; 7:ofaa152Tian S, Liu H, Liao M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32457924>
 33. **C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation.** *Open Forum Infect Dis* 2020; 7:ofaa153Wang G, Wu C, Zhang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455147>
 34. **COVID-19: Komorbiditäten prädisponieren für schweren Verlauf.** *Pneumologie* 2020; 74:257Franke K.
 35. **Clinical Characteristics and Outcomes of COVID-19 Patients With a History of Stroke in Wuhan, China.** *Stroke* 2020;Strokeaha120030365Qin C, Zhou L, Hu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466735>
 36. **A novel simple scoring model for predicting severity of patients with SARS-CoV-2 infection.** *Transbound Emerg Dis* 2020; Dong Y, Zhou H, Li M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469137>

Safety (18 articles)

1. **It is currently unknown whether SARS-CoV-2 is viable in semen or whether COVID-19 damages sperm.** *Andrology* 2020; Perry MJ, Arrington S, Neumann LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471002>
2. **Surgical mask dermatitis caused by formaldehyde (releasers) during the COVID-19 pandemic.** *Contact Dermatitis* 2020; Aerts O, Dendooven E, Foubert K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468589>
3. **Onset of occupational hand eczema among healthcare workers during the SARS-CoV-2 pandemic - comparing a single surgical site with a COVID-19 intensive care unit.** *Contact Dermatitis* 2020; Guertler A, Moellhoff N, Schenck TL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452036>
4. **Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.** *Crit. Rev. Oncol. Hematol.* 2020; 151:102982Jafari A, Dadkhahfar S, Perseh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460133>
5. **Moderate to severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak.** *Dermatol Ther* 2020; Giulia R, Alice R, Teresa FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447800>
6. **More harm than good?: COVID-19 treatment with chloroquine and hydroxychloroquine hides high risks.** *Deutsche Apotheker Zeitung* 2020; 60Jungmayr P.
7. **Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients.** *Diabetes Metab.* 2020; Marfella R, Paolisso P, Sardu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447102>

8. **Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence.** *Int J Clin Pract* 2020:e13557 Yousefifard M, Zali A, Zarghi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460369>
9. **Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.** *Int J Environ Res Public Health* 2020; 17Mirabelli M, Chiefari E, Puccio L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456064>
10. **Ramipril in High Risk Patients with COVID-19.** *J Am Coll Cardiol* 2020; Amat-Santos IJ, Santos-Martinez S, Lopez-Otero D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470515>
11. **Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring.** *J Am Heart Assoc* 2020:e017144 Ramireddy A, Chugh H, Reinier K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463348>
12. **Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.** *J Med Virol* 2020; Ma SQ, Zhang J, Wang YS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470160>
13. **Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia.** *J Med Virol* 2020; Teheran AA, Camero G, Hernandez C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458488>
14. **COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis.** *Kidney Blood Press. Res.* 2020:1-6 Perna AF, Capolongo G, Trepiccione F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450560>
15. **Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.** *Life Sci* 2020:117831 Gurung AB, Ali MA, Lee J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450166>
16. **COVID-19 and NSAIDs: A Narrative Review of Knowns and Unknowns.** *Pain Ther* 2020; Pergolizzi JV, Jr., Varrassi G, Magnusson P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447629>
17. **Potential risks of SARS-CoV-2 infection on reproductive health.** *Reprod. Biomed. Online* 2020; Li R, Yin T, Fang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466994>
18. **[Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)].** *Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi* 2020; 32:119-122 Gao Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458599>

Treatment options (79 articles)

1. **Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit.** *Aaps j* 2020; 22:77 Sun D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458279>
2. **An update on ACE2 amplification and its therapeutic potential.** *Acta Physiol. (Oxf.)* 2020:e13513 Marquez A, Wysocki J, Pandit J, Batlle D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469114>
3. **Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.** *Aging (Albany NY)* 2020; 12Menendez JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463794>
4. **Microbicidal Actives with Virucidal Efficacy against SARS-CoV-2.** *Am. J. Infect. Control* 2020; Ijaz MK, Nims RW, Whitehead K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461067>
5. **A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization.** *Biochem. Biophys. Res. Commun.* 2020; Bongini P, Trezza A, Bianchini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451080>
6. **Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.** *Biomedicines* 2020; 8Glinsky GV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32455629>
7. **Cytokine Blood Filtration Responses in COVID-19.** *Blood Purif.* 2020:1-9 Al Shareef K, Bakouri M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464624>
8. **Efficacy of therapeutic plasma exchange in severe COVID-19 patients.** *Br. J. Haematol.* 2020; Zhang L, Zhai H, Ma S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453903>
9. **Lymphopenia in COVID-19: Therapeutic Opportunities.** *Cell Biol. Int.* 2020; Fathi N, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458561>
10. **A Role for Retinoids in The Treatment of Covid-19?** *Clin. Exp. Pharmacol. Physiol.* 2020; Trasino SE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459003>
11. **Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.** *Clin Infect Dis* 2020; Raabe VN, Lighter J, Caplan AL, Ratner AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459832>
12. **Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.** *Clin Microbiol Infect* 2020; Rodrigo C, Fernando SD, Rajapakse S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470568>
13. **Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.** *Crit. Rev. Oncol. Hematol.* 2020; 151:102982 Jafari A, Dadkhahfar S, Perseh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460133>
14. **Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?** *Dermatol Ther* 2020; Seirafianpour F, Mozafarpour S, Fattahi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473070>
15. **Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.** *Dermatol Ther* 2020:e13668 Yu Olisova O, Anpilogova EM, Svistunova DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449265>
16. **TCM in the fight against COVID-19?: The traditional medicine from the Far East is expected to become an export hit, the benefit is unclear.** *Deutsche Apotheker Zeitung* 2020; 60.
17. **More harm than good?: COVID-19 treatment with chloroquine and hydroxychloroquine hides high risks.** *Deutsche Apotheker Zeitung* 2020; 60Jungmayr P.
18. **Remedy for scabies against COVID-19: In vitro efficacy of ivermectin is waiting for clinical confirmation.** *Deutsche Apotheker Zeitung* 2020; 60Richling AI.
19. **Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients.** *Diabetes Metab.* 2020; Marfella R, Paolisso P, Sardu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447102>

20. **Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.** *Diabetes Metab Syndr* 2020; 14:713-714 Erol A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470851>
21. **The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.** *Eur Heart J Cardiovasc Pharmacother* 2020; Offringa A, Montijn R, Singh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464637>
22. **Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.** *Eur J Intern Med* 2020; Morena V, Milazzo L, Oreni L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448770>
23. **Facing SARS-CoV-2 outbreak in immunotherapy era.** *Future Oncol* 2020; Citarella F, Russano M, Pantano F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468851>
24. **Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review.** *Infect Dis Ther* 2020; Fajgenbaum DC, Khor JS, Gorzewski A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462545>
25. **A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic.** *Int J Antimicrob Agents* 2020:106028 Tripathy S, Dassarma B, Roy S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450198>
26. **High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.** *Int. J. Biol. Macromol.* 2020; Naik B, Gupta N, Ojha R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470577>
27. **Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.** *Int J Infect Dis* 2020; Jang S, Rhee JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470602>
28. **Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification.** *Int J Infect Dis* 2020; Wang Q, Hu Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470601>
29. **Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.** *Int J Mol Sci* 2020; 21 Gimeno A, Mestres-Truyol J, Ojeda-Montes MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471205>
30. **Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.** *Int J Mol Sci* 2020; 21 Orienti I, Gentilomi GA, Farruggia G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471278>
31. **Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?** *Int J Mol Sci* 2020; 21 Rossi F, Tortora C, Argenziano M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471272>
32. **Trials and tribulations: so many potential treatments, so few answers.** *Int. Orthop.* 2020; Gazendam A, Nucci N, Ekhtiari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447429>
33. **Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?** *Intern Emerg Med* 2020; Depfenhart M, de Villiers D, Lemperle G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458206>
34. **Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.** *Intern Emerg Med* 2020; Perotti C, Del Fante C, Baldanti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468508>
35. **Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.** *J Allergy Clin Immunol* 2020; Cao Y, Wei J, Zou L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470486>
36. **Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring.** *J Am Heart Assoc* 2020:e017144 Ramireddy A, Chugh H, Reinier K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463348>
37. **Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.** *J Biol Regul Homeost Agents* 2020; 34 Marini S, Maggiorotti M, Dardes N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462858>
38. **Molecular Docking, Simulation and MM-PBSA Studies of Nigella Sativa Compounds: A Computational Quest to identify Potential Natural Antiviral for COVID-19 Treatment.** *J Biomol Struct Dyn* 2020:1-16 Ahmad S, Abbasi HW, Shahid S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462996>
39. **Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs.** *J Biomol Struct Dyn* 2020:1-11 Amin M, Abbas G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469265>
40. **In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2.** *J Biomol Struct Dyn* 2020:1-25 Beura S, Prabhakar C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448039>
41. **Fragment tailoring strategy to design novel chemical entities as potential binders of novel coronavirus main protease.** *J Biomol Struct Dyn* 2020:1-15 Choudhury C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452282>
42. **Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.** *J Biomol Struct Dyn* 2020:1-14 de Oliveira OV, Rocha GB, Paluch AS, Costa LT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448085>
43. **Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches.** *J Biomol Struct Dyn* 2020:1-21 Kumar A, Choudhir G, Shukla SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448034>
44. **Withanone and withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.** *J Biomol Struct Dyn* 2020:1-27 Kumar V, Dhanjal JK, Bhargava P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469279>
45. **Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.** *J Clin Med* 2020; 9 Ang L, Song E, Lee HW, Lee MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32456123>
46. **Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.** *J Infect* 2020; Klement-Frutos E, Burrell S, Peytavin G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473230>
47. **Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine.** *J Integr Med* 2020; Wang SX, Wang Y, Lu YB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446813>
48. **COVID-19 pneumonia treated with Sarilumab: a clinical series of eight patients.** *J Med Virol* 2020; Benucci M, Giannasi G, Cecchini P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472703>

49. **Glycyrrhetic acid and its derivatives as potential alternative medicine to relieve symptoms in non-hospitalized COVID-19 patients.** *J Med Virol* 2020; Ding H, Deng W, Ding L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458502>
50. **Compassionate use of hzV5F-v13 in two patients with severe COVID-19.** *J Med Virol* 2020; Kang CK, Choe PG, Park S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458425>
51. **Current regulatory approaches for accessing potential COVID-19 therapies.** *J Pharm Policy Pract* 2020; 13:16Halimi V, Daci A, Stojanovska S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454981>
52. **In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.** *Korean J. Intern. Med.* 2020; Kang CK, Seong MW, Choi SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460458>
53. **The world is waiting, use sequential analysis and get us the evidence-based treatment we need for COVID-19.** *Libyan J. Med.* 2020; 15:1770518El Taguri A, Nasef A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32459574>
54. **Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.** *Life Sci* 2020:117842Banerjee A, Czinn SJ, Reiter RJ, Blanchard TG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454157>
55. **Coronaviruses pandemics: Can neutralizing antibodies help?** *Life Sci* 2020:117836Tong PB, Lin LY, Tran TH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450171>
56. **Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.** *Med. Hypotheses* 2020; 143:109871Allahverdi Khani M, SalehiRad M, Darbeheshti S, Motaghinejad M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470789>
57. **Zinc iodide in combination with Dimethyl Sulfoxide for treatment of SARS-CoV-2 and other viral infections.** *Med. Hypotheses* 2020; 143:109866Hoang BX, Hoang HQ, Han B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473509>
58. **Selenium supplementation in the prevention of coronavirus infections (COVID-19).** *Med. Hypotheses* 2020; 143:109878Kieliszek M, Lipinski B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464491>
59. **A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?** *Microb. Pathog.* 2020:104277Divya M, Vijayakumar S, Chen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473390>
60. **Why have nanotechnologies been underutilized in the global uprising against the coronavirus pandemic?** *Nanomedicine (Lond)* 2020; Uskokovic V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462968>
61. **Vitamin D can prevent COVID-19 infection-induced multiple organ damage.** *Naunyn Schmiedebergs Arch. Pharmacol.* 2020; Aygun H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451597>
62. **Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.** *Naunyn Schmiedebergs Arch. Pharmacol.* 2020; Rizzo E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462282>
63. **Possible Role of Adipose Tissue and Endocannabinoid System in COVID-19 Pathogenesis: Can Rimonabant Return?** *Obesity (Silver Spring)* 2020; Briand-Mesange F, Trudel S, Salles J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32463562>
64. **Excess Ascorbate is a Chemical Stress Agent against Proteins and Cells.** *Pharmaceuticals (Basel)* 2020; 13Lehene M, Fischer-Fodor E, Scurtu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471171>
65. **Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.** *Pharmacol. Res.* 2020; 158:104901Cheong DHJ, Tan DWS, Wong FWS, Tran T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32461197>
66. **Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.** *Pharmacol. Res.* 2020:104950Viecca M, Radovanovic D, Forleo GB, Santus P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450344>
67. **Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.** *Pharmacol. Res.* 2020:104960Yuan S, Chan JFW, Chik KKH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473310>
68. **Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.** *Pharmacol. Ther.* 2020:107587Liu T, Luo S, Libby P, Shi GP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470470>
69. **Cytokine storm in COVID-19 and parthenolide: preclinical evidence.** *Phytother. Res.* 2020; Bahrami M, Kamalinejad M, Latifi SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472655>
70. **Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.** *Stem Cell. Res. Ther.* 2020; 11:207Zhang Y, Ding J, Ren S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460839>
71. **Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.** *Stem Cells Transl Med* 2020; Qu W, Wang Z, Hare JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472653>
72. **Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.** *Transfus. Apher. Sci.* 2020:102794Seghatchian J, Lanza F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448638>
73. **COVID-19: are neutralizing antibodies neutralizing enough?** *Transfusion* 2020; Kadkhoda K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449171>
74. **Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab.** *Transpl Infect Dis* 2020:e13334Lauterio A, Valsecchi M, Santambrogio S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449235>
75. **Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.** *Trials* 2020; 21:422Wang Y, Zhou F, Zhang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448345>
76. **Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.** *Vox Sang* 2020; Epstein J, Smid M, Wendel S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32464700>
77. **[Feasibility analysis on acupuncture therapy for the treatment of Corona Virus Disease 2019 and the exploration on the application scheme].** *Zhen Ci Yan Jiu* 2020; 45:345-350Wang RQ, Liu JX, Zhang ZD

- et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447846>
78. [Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)]. *Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi* 2020; 32:119-122 Gao Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458599>
 79. [Application of convalescent plasma therapy on novel coronavirus infection]. *Zhonghua Jie He He Hu Xi Za Zhi* 2020; 43:409-413 Zhao Q, He Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32450629>

Trials (11 articles)

1. Review of trials currently testing treatment and prevention of COVID-19. *Clin Microbiol Infect* 2020; Fragkou PC, Belhadi D, Peiffer-Smadja N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454187>
2. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. *Diabetologia* 2020; Cariou B, Hadjadj S, Wargny M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472191>
3. Trials and tribulations: so many potential treatments, so few answers. *Int. Orthop.* 2020; Gazendam A, Nucci N, Ekhtiari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32447429>
4. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol. *Intern Emerg Med* 2020; Perotti C, Del Fante C, Baldanti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468508>
5. Ramipril in High Risk Patients with COVID-19. *J Am Coll Cardiol* 2020; Amat-Santos IJ, Santos-Martinez S, Lopez-Otero D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470515>
6. The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials. *J Am Coll Cardiol* 2020; Bagiella E, Bhatt DL, Gaudino M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470514>
7. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study. *J Biol Regul Homeost Agents* 2020; 34 Marini S, Maggiorotti M, Dardes N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32462858>
8. Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses. *Trends Pharmacol Sci* 2020; Ma Z, Liu J, Pan Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471655>
9. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. *Trials* 2020; 21:422 Wang Y, Zhou F, Zhang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32448345>
10. Efficacy of Liu-zi-jue in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19): structured summary of a study protocol for a randomized controlled trial. *Trials* 2020; 21:416 Zhang S, Lv Z, Zhu Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32446311>
11. Challenges in Tuberculosis Clinical Trials in the Face of the COVID-19 Pandemic: A Sponsor's Perspective. *Trop Med Infect Dis* 2020; 5 Rusen ID. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471274>

Vaccines (4 articles)

Impfstoffe

1. COVID-19 challenge: Feverish search for vaccines and antiviral therapies. *Deutsche Apotheker Zeitung* 2020; 160 Blasius H.
2. Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics. *Eur. J. Pharm. Sci.* 2020; 105387 Ahmad S, Navid A, Farid R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32454128>
3. Vaccine Rationing and the Urgency of Social Justice in the Covid-19 Response. *Hastings Cent Rep* 2020; Schmidt H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32468631>
4. The early landscape of COVID-19 vaccine development in the UK and rest of the world. *Immunology* 2020; Sharpe HR, Gilbride C, Allen E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460358>

Women – pregnancy (27 articles)

Frauen – Schwangerschaft

1. Uptrend in distress and psychiatric symptomatology in pregnant women during the COVID-19 pandemic. *Acta Obstet Gynecol Scand* 2020; Berthelot N, Lemieux R, Garon-Bissonnette J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449178>
2. Age-related difference in the rate of COVID-19 mortality in women versus men. *Am J Obstet Gynecol* 2020; Cagnacci A, Xholli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460973>
3. COVID-19: Safe Guidelines for Breast Imaging During the Pandemic. *Can Assoc Radiol J* 2020; 846537120928864 Seely JM, Scaranelo AM, Yong-Hing C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452700>
4. Low prevalence of SARS-CoV-2 among pregnant and postpartum patients with universal screening in Seattle, Washington. *Clin Infect Dis* 2020; LaCourse SM, Kachikis A, Blain M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472688>
5. Detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human breast milk of a mildly symptomatic patient with coronavirus disease 2019 (COVID-19). *Clin Infect Dis* 2020; Tam PCK, Ly KM, Kernich ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472683>
6. A new diagnostic strategy for gestational diabetes during the COVID-19 pandemic for the Japanese population. *Diabetes Metab Res Rev* 2020; e3351 Kasuga Y, Saisho Y, Ikenoue S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32453497>
7. Diabetes and pregnancy—update 2020. *Diabetologie* 2020; Kleinwechter H.
8. The gendered impact of coronavirus disease (COVID-19): do estrogens play a role? *Eur. J. Contracept. Reprod. Health Care* 2020; 1-2 Grandi G, Facchinetti F, Bitzer J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32469251>
9. Management of a delivery suite during the COVID-19 epidemic. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2020; Qi H, Chen M, Luo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466867>

10. **Challenges and solutions for maternity and gynecology services during the COVID-19 crisis in Jordan.** *Int J Gynaecol Obstet* 2020; Alsharaydeh I, Rawashdeh H, Saadeh N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32470178>
11. **Practical recommendations for gynecologic surgery during the COVID-19 pandemic.** *Int J Gynaecol Obstet* 2020; Chiofalo B, Baiocco E, Mancini E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471012>
12. **Maternal mortality from COVID-19 in Mexico.** *Int J Gynaecol Obstet* 2020; Lumbreras-Marquez MI, Campos-Zamora M, Lizaola-Diaz de Leon H, Farber MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473603>
13. **Healthcare information on YouTube: Pregnancy and COVID-19.** *Int J Gynaecol Obstet* 2020; Yuksel B, Cakmak K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32471005>
14. **Gynecologic oncology at the time of COVID-19 outbreak.** *J Gynecol Oncol* 2020; Bogani G, Brusadelli C, Guerriero R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458597>
15. **Recommendations on management of gynecological malignancies during the COVID-19 pandemic: perspectives from Chinese gynecological oncologists.** *J Gynecol Oncol* 2020; Wang Y, Zhang S, Wei L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458596>
16. **Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond.** *J Natl. Cancer Inst.* 2020; Freedman RA, Sedrak MS, Bellon JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449757>
17. **COVID-19 and pregnancy - where are we now? A review.** *J. Perinat. Med.* 2020; Rajewska A, Mikolajek-Bedner W, Lebdowicz-Knul J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32452195>
18. **SARS-CoV-2 and human milk: What is the evidence?** *Matern. Child Nutr.* 2020:e13032Lackey KA, Pace RM, Williams JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32472745>
19. **COVID-19, food and nutrition insecurity and the wellbeing of children, pregnant and lactating women: A complex syndemic.** *Matern. Child Nutr.* 2020:e13036Perez-Escamilla R, Cunningham K, Moran VH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458574>
20. **When Separation is not the Answer: Breastfeeding Mothers and Infants affected by COVID-19.** *Matern. Child Nutr.* 2020:e13033Tomori C, Gribble K, Palmquist AEL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458558>
21. **COVID-19 and fertility: a virtual reality.** *Reprod. Biomed. Online* 2020; Anifandis G, Messini CI, Daponte A, Messinis IE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466995>
22. **Potential risks of SARS-CoV-2 infection on reproductive health.** *Reprod. Biomed. Online* 2020; Li R, Yin T, Fang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32466994>
23. **A picture of the covid-19 impact on IVIRMA fertility treatment clinics in Spain and Italy.** *Reprod. Biomed. Online* 2020; Requena A, Cruz M, Vergara V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32451301>
24. **[Coronavirus Covid-19 infection and breastfeeding: an exploratory review].** *Rev. Esp. Salud Publica* 2020; 94Fernandez-Carrasco FJ, Vazquez-Lara JM, Gonzalez-Mey U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32458823>
25. **Access to later abortion in the United States during COVID-19: Challenges and recommendations from providers, advocates, and researchers.** *Sex Reprod Health Matters* 2020:1-4Ruggiero S, Brandi K, Mark A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32460663>
26. **Screening for COVID-19 at childbirth: does it deliver?** *Ultrasound Obstet Gynecol* 2020; Ceulemans D, Thijs I, Schreurs A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449230>
27. **Prevention of thrombosis in pregnant women with suspected SARS-CoV-2 infection: clinical management algorithm.** *Ultrasound Obstet Gynecol* 2020; Lou-Mercade AC, Gavin O, Oros D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32449242>

to subscribe click [here](#)
